<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">92775</article-id><article-id pub-id-type="doi">10.7554/eLife.92775</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.92775.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Brain-derived and in vitro-seeded alpha-synuclein fibrils exhibit distinct biophysical profiles</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Selene Seoyun</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2801-6202</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Civitelli</surname><given-names>Livia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2399-1436</contrib-id><email>livia.civitelli@ndcn.ox.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Parkkinen</surname><given-names>Laura</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3392-8564</contrib-id><email>laura.parkkinen@ndcn.ox.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>Nuffield Department of Clinical Neurosciences, Oxford Parkinson’s Disease Center, University of Oxford</institution></institution-wrap><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Mistry</surname><given-names>Pramod K</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Yale University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Mistry</surname><given-names>Pramod K</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Yale University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>25</day><month>11</month><year>2024</year></pub-date><volume>13</volume><elocation-id>RP92775</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-09-28"><day>28</day><month>09</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-10-06"><day>06</day><month>10</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.10.04.560803"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-03-21"><day>21</day><month>03</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.92775.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-10-03"><day>03</day><month>10</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.92775.2"/></event></pub-history><permissions><copyright-statement>© 2024, Lee et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Lee et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-92775-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-92775-figures-v1.pdf"/><abstract><p>The alpha-synuclein (αSyn) seeding ampliﬁcation assay (SAA) that allows the generation of disease-speciﬁc in vitro seeded ﬁbrils (SAA ﬁbrils) is used as a research tool to study the connection between the structure of αSyn fibrils, cellular seeding/spreading, and the clinicopathological manifestations of different synucleinopathies. However, structural differences between human brain-derived and SAA αSyn ﬁbrils have been recently highlighted. Here, we characterize the biophysical properties of the human brain-derived αSyn ﬁbrils from the brains of patients with Parkinson’s disease with and without dementia (PD, PDD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and compare them to the ‘model’ SAA ﬁbrils. We report that the brain-derived αSyn ﬁbrils show distinct biochemical proﬁles, which were not replicated in the corresponding SAA ﬁbrils. Furthermore, the brain-derived αSyn ﬁbrils from all synucleinopathies displayed a mixture of ‘straight’ and ‘twisted’ microscopic structures. However, the PD, PDD, and DLB SAA ﬁbrils had a ’straight’ structure, whereas MSA SAA ﬁbrils showed a ‘twisted’ structure. Finally, the brain-derived αSyn ﬁbrils from all four synucleinopathies were phosphorylated (S129). Interestingly, phosphorylated αSyn were carried over to the PDD and DLB SAA fibrils. Our ﬁndings demonstrate the limitation of the SAA ﬁbrils modeling the brain-derived αSyn ﬁbrils and pay attention to the necessity of deepening the understanding of the SAA fibrillation methodology.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>Alpha-synuclein is a protein that is essential for brain function. Like all proteins, alpha-synuclein is made of a string of amino acids and folded up in a precise way. Misfolding of this protein can lead to a buildup of protein clumps in the brain. These clumps cause neurodegenerative diseases like Parkinson’s disease, Parkinson’s disease with dementia, dementia with Lewy bodies, and multiple system atrophy.</p><p>Each of these diseases affects different parts of the brain and has distinct symptoms. Studying the misfolding patterns and structures of proteins collected from the brains of deceased people who had these conditions may help scientists understand the differences. Scientists also try to recreate these misfolded proteins in the laboratory using a seeding amplification assay technique. This is important as scientists can only extract limited amounts of protein clumps from human brains. However, it is unclear if the laboratory-produced protein clumps behave exactly like brain-derived clumps. Learning more is essential to make sure that studies of these proteins produce accurate results.</p><p>Lee et al. identified differences between alpha-synuclein clumps extracted from patients with different brain diseases. They also show that laboratory-derived protein clumps do not exactly recreate those from patients. Clumps from patients with Parkinson’s disease, Parkinson’s disease with dementia, dementia with Lewy bodies, and multiple system atrophy have straight and twisted protein structures when examined under an electron microscope. But the laboratory-generated clumps for Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies are all straight. Laboratory-generated clumps for multiple system atrophy are all twisted. The clumps from patient brains also have many phosphate groups attached to them. Laboratory-derived clumps of Parkinson’s disease with dementia and dementia with Lewy bodies also had this feature. However, the lab-derived versions of the other disease clumps lack this characteristic.</p><p>Lee et al. identify essential differences between the protein clumps from the brains of patients with different neurodegenerative diseases. They also found that the laboratory-generated clumps do not completely replicate all their features. More research is needed on these disease-specific differences and how they contribute to specific disease symptoms and disease progress. Work is also required to refine laboratory processes for protein clumps to replicate disease-associated clumps better. More studies could help scientists develop better laboratory models for these diseases that can be used to create and test new therapies.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Alpha-synuclein</kwd><kwd>seeded amplification assay</kwd><kwd>strains</kwd><kwd>Synucleinopathies</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Oxford-GSK Institute of Molecular and Computational Medicine</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Parkkinen</surname><given-names>Laura</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100013373</institution-id><institution>NIHR Oxford Biomedical Research Centre</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Civitelli</surname><given-names>Livia</given-names></name><name><surname>Parkkinen</surname><given-names>Laura</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100013301</institution-id><institution>Parkinson's Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Parkkinen</surname><given-names>Laura</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000864</institution-id><institution>Michael J Fox Foundation for Parkinson's Disease Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Parkkinen</surname><given-names>Laura</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>Galen and Hilary Weston Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Parkkinen</surname><given-names>Laura</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Parkkinen</surname><given-names>Laura</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The in-vitro seeded fibrils are unlikely to be disease-relevant and representative of the diverse alpha-synuclein polymorphs in the brain.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Synucleinopathies are all characterized by abnormal accumulation of the protein αSyn in the brain. However, they are clinically and neuropathologically highly heterogeneous diseases with prominent disease-specific differences in the presentation of symptoms, rate of disease progression, and the brain regions and cell types are vulnerable to αSyn deposition and neuronal death. In PD, PDD, and DLB, αSyn aggregation is found in the neuronal soma as Lewy bodies (LBs) and in the axons and dendrites as Lewy neurites (LNs) (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="bibr" rid="bib17">Forno, 1988</xref>; <xref ref-type="bibr" rid="bib52">Spillantini et al., 1997</xref>; <xref ref-type="bibr" rid="bib9">Braak et al., 2003</xref>). Furthermore, the astroglial accumulation of αSyn is a prominent but so far underdiagnosed pathology in these Lewy body disorders (<xref ref-type="bibr" rid="bib3">Altay et al., 2022</xref>). The αSyn pathology in MSA is primarily found in oligodendrocytes as glial cytoplasmic inclusions (GCIs) (<xref ref-type="bibr" rid="bib39">Papp et al., 1989</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Distinct alpha-synuclein (αSyn) strains are associated with different neuropathological and clinical hallmarks of Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA).</title><p>αSyn misfolds and aggregates into fibrils with characteristic conformations. At the atomic level, PD and DLB strains share a ‘Lewy fold’ structure at the fibrillar core and comprise a single protofilament (<xref ref-type="bibr" rid="bib65">Yang et al., 2022</xref>). MSA strains are twisted with two protofilaments intertwined, forming a different core structure to the ‘Lewy fold’ (<xref ref-type="bibr" rid="bib47">Schweighauser et al., 2020</xref>). At a cellular level, PD is characterized by significant neuronal loss at the brainstem, especially substantia nigra (SN), highlighted in blue. Lewy body (LB) and Lewy neurite (LN) accumulate in neurons. αSyn also accumulates in astrocytes, forming astroglial pathology. In DLB, the brainstem and neocortex are the most affected regions, highlighted in green. Here, LB and LN accumulate in neurons, and astroglial pathology is also observed. In MSA, the cerebellum, basal ganglia, and brainstem are the most affected, highlighted in red. Here, αSyn accumulates as glial cytoplasmic inclusions (GCIs) in the oligodendrocytes. The 3D structures of the αSyn fibrillar cores were generated using PyMOL, and the PDB structures from <xref ref-type="bibr" rid="bib47">Schweighauser et al., 2020</xref>; <xref ref-type="bibr" rid="bib65">Yang et al., 2022</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92775-fig1-v1.tif"/></fig><p>The mechanistic link between αSyn and clinicopathological diversity of the synucleinopathies is hypothesized to be the different ﬁbrillar ‘strains’ of αSyn in analogy to prion disease. A strain is generated when αSyn monomers fold into speciﬁc ﬁbrillar forms with distinct conformational and biological characteristics (<xref ref-type="bibr" rid="bib38">Melki, 2018</xref>). Under the disease condition, misfolded and aggregated αSyn recruits normal, soluble endogenous αSyn to aggregate, and this self-perpetuating process spreads throughout the brain-periphery axis. Several studies have generated αSyn ﬁbrils in vitro using various experimental conditions to characterize the presence of different strains (<xref ref-type="bibr" rid="bib8">Bousset et al., 2013</xref>; <xref ref-type="bibr" rid="bib40">Peelaerts et al., 2015</xref>; <xref ref-type="bibr" rid="bib32">Li et al., 2018</xref>; <xref ref-type="bibr" rid="bib22">Guerrero-Ferreira et al., 2019</xref>; <xref ref-type="bibr" rid="bib29">Lau et al., 2020</xref>), but their relevance to the human condition remains questionable. However, some studies have also examined αSyn fibrils extracted from the human brain tissue of different synucleinopathies and these have demonstrated that the human-derived αSyn strains exhibit distinct structures (<xref ref-type="bibr" rid="bib47">Schweighauser et al., 2020</xref>), infectivity and bioactivity in cells (<xref ref-type="bibr" rid="bib60">Woerman et al., 2018a</xref>; <xref ref-type="bibr" rid="bib62">Woerman et al., 2019</xref>; <xref ref-type="bibr" rid="bib4">Ayers et al., 2022</xref>) and animals (<xref ref-type="bibr" rid="bib43">Prusiner et al., 2015</xref>; <xref ref-type="bibr" rid="bib29">Lau et al., 2020</xref>; <xref ref-type="bibr" rid="bib26">Holec et al., 2022</xref>; <xref ref-type="bibr" rid="bib41">Peng et al., 2018</xref>). The intrinsic structure of αSyn proteoforms may also depend on the local conditions of the brain region where they are formed and thus may vary within a single disease entity (<xref ref-type="bibr" rid="bib41">Peng et al., 2018</xref>; <xref ref-type="bibr" rid="bib29">Lau et al., 2020</xref>; <xref ref-type="bibr" rid="bib47">Schweighauser et al., 2020</xref>). Future studies must comprehensively map the distinct fingerprints of human brain-derived αSyn strains to the disease.</p><p>SAAs have become more applicable due to their feasibility in amplifying in vitro-seeded αSyn ﬁbrils (SAA ﬁbrils) from human biosamples. SAA refers to two distinct seed amplification techniques: real-time quaking-induced conversion (RT-QuIC) and protein misfolding cyclic amplification (PMCA). Both methods incorporate a key characteristic of pathological αSyn, which is its ability to induce aggregation of monomeric αSyn into different complex conformers. When pathological αSyn is present in the biosample, it seeds aggregation of the recombinant αSyn in the reaction through repeated elongation-fragmentation cycles (<xref ref-type="bibr" rid="bib12">Concha-Marambio et al., 2023</xref>). A major difference between the two methods lies in the method of aggregate fragmentation (<xref ref-type="bibr" rid="bib13">Coysh and Mead, 2022</xref>). RT-QuIC uses physical shaking, and PMCA uses sonication. Also, the RT-QuIC reaction is monitored automatically in real-time using a fluorophore such as Thioflavin-T (ThT), whereas PMCA requires manual measurement. Furthermore, it should be noted that the RT-QuIC products are not infectious, while the PMCA produces infectious aggregates with specific strain fidelity (<xref ref-type="bibr" rid="bib44">Raymond et al., 2020</xref>). In this study, RT-QuIC has been selectively used and referred to as ‘SAA’.</p><p>SAA, together with different biosamples such as cerebrospinal ﬂuid (CSF) (<xref ref-type="bibr" rid="bib16">Fairfoul et al., 2016</xref>; <xref ref-type="bibr" rid="bib42">Poggiolini et al., 2022</xref>), brain homogenates (<xref ref-type="bibr" rid="bib21">Groveman et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Sano et al., 2018</xref>), and skin punctures (<xref ref-type="bibr" rid="bib35">Mammana et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">Kuzkina et al., 2021</xref>), has presented its potential as a diagnostic method but also as a research tool to amplify disease-relevant ﬁbrils. The newly ampliﬁed SAA ﬁbrils are assumed to encode the intrinsic properties of the original seeding fibrils, thus being representative of the disease-speciﬁc strains. Therefore, using the ‘model’ SAA ﬁbrils, studies have shown disease-speciﬁc structural, biochemical, and phenotypic differences, suggesting the presence of distinct conformational αSyn strains in different synucleinopathies (<xref ref-type="bibr" rid="bib54">Strohäker et al., 2019</xref>; <xref ref-type="bibr" rid="bib49">Shahnawaz et al., 2020</xref>; <xref ref-type="bibr" rid="bib57">Van der Perren et al., 2020</xref>; <xref ref-type="bibr" rid="bib18">Frieg et al., 2022</xref>).</p><p>Despite such extensive strain characterisation performed with the SAA fibrils, whether the SAA fibrils are representative models of the original seed fibrils is unclear. Studies highlighted the significant structural differences between the human brain-derived and SAA ﬁbrils (<xref ref-type="bibr" rid="bib33">Lövestam et al., 2021</xref>) and seeded pathology in vivo (<xref ref-type="bibr" rid="bib57">Van der Perren et al., 2020</xref>). Nevertheless, there is currently a limited understanding of whether the resulting SAA ﬁbrils preserve other properties, including biochemical, biophysical, cellular toxicity, and pathology.</p><p>Here, we aim to investigate the biophysical differences between (1) the brain-derived αSyn ﬁbrils in different synucleinopathies and (2) the brain-derived αSyn versus the corresponding SAA ﬁbrils. We examine the brain-derived αSyn fibrils extracted from the brains of patients with PD, PDD, DLB, and MSA and the brain-derived versus SAA αSyn ﬁbrils and show striking, differences in their biochemical proﬁle, structure, and phosphorylation pattern. Our ﬁndings reveal further evidence supporting the molecular diversity among αSyn fibrils from different synucleinopathies. Also, our study highlights the limitations of the SAA ﬁbrils to fully mirror the brain-derived αSyn ﬁbrils and the need to study further the mechanism of seeding amplification and the application of SAA fibrils.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Detection of differential αSyn seeding activity from brain-derived fibrils of PD, PDD, DLB, and MSA</title><p>We extracted αSyn fibrils from the human brain of patients with PD (n=3), PDD (n=3), DLB (n=3), MSA (n=3), and healthy controls (n=3) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). The entorhinal cortex was used for PD, PDD, and DLB, and the striatum for MSA, as these are some of the main affected regions with αSyn pathology in each disorder. The brain-derived ﬁbrils were diluted 1: 1000 and used as a seed in an SAA reaction to generate in vitro ampliﬁed ﬁbrils (SAA ﬁbrils). PD, PDD, DLB, and MSA brain-derived αSyn fibrils reached the maximum ThT fluorescence within 100 hr (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). The healthy controls did not display seeding potential except for case 2 (HC 2), which showed an increasing signal towards the end of the reaction (approximately 91 hr) (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). The unseeded recombinant αSyn remained negative in all reactions (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). The raw data of all the replicates are presented in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>. Kinetic parameters revealed a statistical difference in the seeding activities between PD/MSA and PDD/DLB. The time to reach 50% of the maximum fluorescence (<inline-formula><mml:math id="inf1"><mml:msub><mml:mi>T</mml:mi><mml:mn>50</mml:mn></mml:msub></mml:math></inline-formula>) and the lag phase (time to reach five standard deviations of the minimum fluorescence) were significantly lower in PDD/DLB than in PD/MSA (Figure fig:<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>). As a result, the area under the curve (AUC) was statistically higher in PDD/DLB than in PD/MSA (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). However, the maximum rate of increase in fluorescence (<inline-formula><mml:math id="inf2"><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mtext/><mml:mi>MAX</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>) was not statistically different among the diseases (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Overall, the SAA kinetic parameters suggest PDD and DLB brain-derived αSyn fibrils have a more aggressive seeding capacity than PD and MSA.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Alpha-synuclein (αSyn) seeding amplification assay (SAA) seeded with αSyn fibrils from Parkinson’s disease (PD), Parkinson’s disease with dementia (PDD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA) brains.</title><p>(<bold>A</bold>) SAA was performed with sarkosyl insoluble fractions of PD (n=3), PDD (n=3), DLB (n=3), MSA (n=3), and HC (n=3) brains. The curves represent an average of six replicates. Rec αSyn indicates an unseeded control reaction. (<bold>B</bold>) Time to reach 50% of the maximum fluorescence (<inline-formula><mml:math id="inf3"><mml:msub><mml:mi>T</mml:mi><mml:mn>50</mml:mn></mml:msub></mml:math></inline-formula>). (<bold>C</bold>) The lag phase was taken at the time point where each positive reaction exceeded the threshold (RFU ≥ 5 SD). (<bold>D</bold>) Area under the curve (AUC). (<bold>E</bold>) The largest increase of fluorescence per unit of time (V<sub>MAX</sub>). (<bold>B–E</bold>) Plotted values represent the six replicates of the three cases for each disease (n=18). RFU, relative fluorescence unit; SD, standard deviation. *p≤0.05, **p≤0.01, ***p≤0.005.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92775-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Raw data of the alpha-synuclein (αSyn) seeding amplification assay (SAA) reaction seeded with αSyn fibrils from Parkinson’s disease (PD), Parkinson’s disease with dementia (PDD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and healthy control brains.</title><p>The curves represent the average of 6 replicates, and error bars indicate ± one standard deviation (SD). RFU, relative fluorescence unit.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92775-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Brain-derived and SAA αSyn fibrils display distinct biochemical profiles</title><p>At the end of the SAA reaction, the SAA αSyn fibrils were collected by ultracentrifugation. Having established that prion strains can be characterized by distinct biochemical profiles (<xref ref-type="bibr" rid="bib29">Lau et al., 2020</xref>; <xref ref-type="bibr" rid="bib49">Shahnawaz et al., 2020</xref>; <xref ref-type="bibr" rid="bib45">Sano et al., 2014</xref>), we examined this characteristic in the brain-derived and SAA αSyn fibrils. First, the fibrils were denatured with increasing concentrations of guanidine hydrochloride (GdnHCl, 0–5 M) and then digested with proteinase-K (PK, 1 μg/ml).</p><p>The weakest GdnHCl (1 M) treatment completely denatured the PD and MSA brain-derived αSyn fibrils, as they were no longer visible on the immunoblot (<xref ref-type="fig" rid="fig3">Figure 3</xref>). This result was consistent among all the three cases analyzed (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Higher GdnHCl concentrations of 2 M and 3 M denatured PDD and DLB brain-derived αSyn fibrils, respectively (<xref ref-type="fig" rid="fig3">Figure 3</xref>). The results illustrate that PD and MSA brain-derived αSyn fibrils have weaker biochemical stability than PDD and DLB fibrils.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Brain-derived and SAA alpha-synuclein (αSyn) fibrils exhibited distinct biochemical profiles.</title><p>Brain-derived and SAA αSyn fibrils were subjected to denaturation with increasing concentrations of GdnHCl (0–5 M) and to PK digestion (1 μg/ml). The antibody clone 42 (BD Biosciences) was used to reveal the PK-resistant peptides. Immunoblots of one representative case from Parkinson’s disease (PD), Parkinson’s disease with dementia (PDD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA) are presented. The brain-derived and SAA fibrils are on the top and bottom rows, respectively. The molecular weights of the protein standards are shown in kilodaltons (kDa). Black arrows mark the five PK-resistant peptides revealed in the SAA fibrils. SAA, seeding amplification assay; GndHCl, guanidine-hydrochloride; PK, proteinase-K.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Unedited western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92775-fig3-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Labelled unedited western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92775-fig3-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92775-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>The full biochemical profiles of the brain-derived and SAA alpha-synuclein (αSyn) fibrils from all the cases.</title><p>The brain-derived (BD) and SAA αSyn fibrils from all three cases of (<bold>A</bold>) Parkinson’s disease (PD), (<bold>B</bold>) Parkinson’s disease with dementia (PDD), (<bold>C</bold>) dementia with Lewy bodies (DLB), and (<bold>D</bold>) multiple system atrophy (MSA) were treated with GdnHCl (0-5 M) and PK (1 μg/ml). The antibody clone 42 (BD Biosciences) was used to reveal the PK-resistant peptides. Black arrows mark the five PK-resistant peptides revealed in the SAA fibrils. The molecular weights of the protein standards are shown in kilodaltons (kDa). SAA, seeding amplification assay; GndHCl, guanidine-hydrochloride; PK, proteinase-K.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Unedited western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92775-fig3-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata2"><label>Figure 3—figure supplement 1—source data 2.</label><caption><title>Labelled unedited western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92775-fig3-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92775-fig3-figsupp1-v1.tif"/></fig></fig-group><p>The disappearance of the bands on the immunoblot after GndHCl treatment limited the comparative study of the αSyn fibrils between synucleinopathies. Therefore, we repeated the experiment using PK alone to improve the visualization of the biochemical profiles. The brain-derived αSyn fibrils were treated with five different PK concentrations starting from 0 mg/ml, incrementing to 1 mg/ml. PD cases contained mostly monomeric αSyn (15 kDa) that immediately degraded at the lowest PK concentration (1 ug/ml) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). In contrast, in PDD, DLB, and MSA cases, high molecular weight (MW) bands above 15 kDa were observed, indicative of αSyn aggregates (<xref ref-type="fig" rid="fig4">Figure 4B–D</xref>). Furthermore, lower MW bands (13, 10, 7 kDa) were also observed. As the PK concentration increased, the PDD and DLB fibrils gradually degraded, as the high MW bands started to disappear and low MW bands below 15 kDa began to appear (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>). Similarly, the MSA fibrils gradually degraded as the PK concentration increased (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). However, low MW bands below 15 kDa were less prominent than those of PDD and DLB. These low MW bands were absent in HC (<xref ref-type="fig" rid="fig4">Figure 4E</xref>), and PD and HC showed no difference in the PK profiles.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Proteinase-K degradation patterns of the brain-derived alpha-synuclein (αSyn) fibrils.</title><p>The brain-derived αSyn fibrils from (<bold>A</bold>) Parkinson’s disease (PD), (<bold>B</bold>) Parkinson’s disease with dementia (PDD), (<bold>C</bold>) dementia with Lewy bodies (DLB), (<bold>D</bold>) multiple system atrophy (MSA), and (<bold>E</bold>) HC were subjected to increasing concentrations of proteinase-K (PK) at 0, 0.001, 0.01, 0.1, and 1 mg/ml, represented by the escalating triangular bar. Western blot was performed using the antibody clone 42 (BD Biosciences). The molecular weights of the protein standards are shown in kilodaltons (kDa).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Unedited western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92775-fig4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Labelled unedited western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92775-fig4-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92775-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Immunohistochemical detection of alpha-synuclein (αSyn) in Parkinson’s disease (PD), Parkinson’s disease with dementia (PDD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA) brains.</title><p>The entorhinal cortex (PD, PDD, DLB) and striatum (MSA) were stained with total αSyn using antibody clone 42 (BD Biosciences). (<bold>A–C</bold>) PD cases 1–3. (<bold>D–F</bold>) PDD cases 1–3. (<bold>G–I</bold>) DLB cases 1-3. (<bold>J–L</bold>) MSA cases 1–3. Arrows indicate magnified areas. Scale bars = 20 μm and 200 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92775-fig4-figsupp1-v1.tif"/></fig></fig-group><p>Although we experimented with an identical amount of total protein (10 ug), the amount of αSyn ﬁbril could differ in each brain-derived sample. Using immunohistochemistry, we observed a lower load of αSyn pathology in PD and MSA brains than in PDD and DLB (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). In addition, the brain-derived ﬁbrils were immunogold-labeled with anti-pαSyn and negatively stained for transmission electron microscopy (TEM). The samples were imaged with TEM at low magniﬁcation to observe αSyn ﬁbril density and distribution. PD and MSA cases contained 1–3 αSyn ﬁbrils per region of interest (ROI), whereas PDD and DLB cases contained 3–5 αSyn ﬁbrils per ROI (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Adjacent slot blots also conﬁrmed a higher amount of αSyn ﬁbrils in PDD and DLB than in PD and MSA brain-derived samples. Therefore, lower ﬁbril concentration in the PD and MSA brains could have limited the observation of the PK-resistant peptides using immunoblotting.</p><p>The SAA ﬁbrils revealed markedly different biochemical proﬁles to the brain-derived αSyn ﬁbrils. We observed identical proﬁles among all SAA ﬁbrils from PD, PDD, DLB, and MSA. PK-resistant bands of 7 and 10 kDa started to appear after treatment with 2 M GdnHCl (<xref ref-type="fig" rid="fig3">Figure 3</xref>). However, with increasing concentrations of GdnHCl, speciﬁc PK-resistant peptides appeared, consisting of ﬁve bands (7, 11, 12, 13, 14 kDa) (<xref ref-type="fig" rid="fig3">Figure 3</xref>). These ﬁndings suggest that harsher denaturing conditions are required to destabilize the SAA ﬁbrils and expose PK digestion sites. We concluded that SAA αSyn ﬁbrils are more stable and characterized by distinct biochemical properties than the brain-derived αSyn ﬁbrils.</p></sec><sec id="s2-3"><title>Brain-derived and SAA αSyn fibrils show structural differences</title><p>Next, we used TEM to investigate the structure of the brain-derived and SAA αSyn ﬁbrils. The brain-derived αSyn ﬁbrils from PD, PDD, and DLB exhibited two structures in TEM: straight and twisted (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). The ﬁbrils from MSA were predominantly straight, with the rare presence of twisted type. Therefore, we only considered straight ﬁbrils when comparing the dimensions of the ﬁbrils among synucleinopathies. The length of the ﬁbrils from different synucleinopathies ranged between 68–885 nm. Only the PDD ﬁbrils were signiﬁcantly longer than DLB and MSA (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). The width ranged from 7 to 21 nm, and there were significant differences between the diseases. PD had the widest ﬁbrils, followed by MSA/DLB and PDD (<xref ref-type="fig" rid="fig5">Figure 5C</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Transmission electron microscopy revealed different structures of brain-derived and seeding ampliﬁcation assay (SAA) alpha-synuclein (αSyn) fibrils.</title><p>(<bold>A</bold>) Electron microscope image of negatively stained brain-derived (BD) and SAA fibrils from Parkinson’s disease (PD), Parkinson’s disease with dementia (PDD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA) brains. (<bold>B, C</bold>) The lengths and widths of brain-derived fibrils. (<bold>D, E</bold>) The lengths and width of SAA fibrils. MSA SAA fibrils were twisted with alternating widths, resulting in two clusters of measurements. A total of 30 fibrils from each case were measured and plotted (n=90). Scale bar = 50 nm. *p≤0.05, **p≤0.01, ****p≤0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92775-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Transmission electron microscopy (TEM) images of the twisted brain-derived alpha-synuclein (αSyn) fibrils.</title><p>Parkinson’s disease (PD), Parkinson’s disease with dementia (PDD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA) brain-derived fibrils displayed intertwined fibrils with twists. Helical twists are highlighted in pink and white. Scale bar = 50 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92775-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Comparison of the length and width of the brain-derived and SAA alpha-synuclein (αSyn) fibrils.</title><p>Comparison of the (<bold>A</bold>) lengths and the (<bold>B</bold>) widths of the brain-derived and SAA αSyn fibrils. Thirty fibrils were counted for each case. Thus, a total of 90 data points were plotted (n=90). The black bold line indicates an average. BD, brain-derived; SAA, seeding amplification assay. ****p≤0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92775-fig5-figsupp2-v1.tif"/></fig></fig-group><p>On the other hand, the SAA ﬁbrils demonstrated a single dominant structure. PD, PDD, and DLB SAA ﬁbrils were all straight, and MSA SAA ﬁbrils were all twisted (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Unlike the brain-derived ﬁbrils, the SAA ﬁbrils were highly clustered. The length of the SAA ﬁbrils ranged from 104 to 1008 nm, and PDD/DLB SAA ﬁbrils were signiﬁcantly longer than those of PD/MSA (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). The width ranged from 8 to 25 nm, and the widths of the MSA SAA ﬁbrils were distributed into two groups due to the alternating widths arising from the twisted structure. Unlike the brain-derived ﬁbrils, the average widths of the SAA ﬁbrils were similar between different synucleinopathies (<xref ref-type="fig" rid="fig5">Figure 5E</xref>).</p><p>Overall, in DLB, the SAA ﬁbrils were signiﬁcantly longer and wider than the brain-derived ﬁbrils (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). SAA ﬁbrils from PDD were wider than the brain-derived ﬁbrils but not different in length. The dimensions of the brain-derived and SAA ﬁbrils from PD and MSA were not significantly different. However, it was difficult to compare the dimensions of the MSA ﬁbrils as the brain-derived and SAA ﬁbrils had different morphologies. Our observations demonstrate that brain-derived and SAA αSyn ﬁbrils exhibit distinct TEM structures.</p></sec><sec id="s2-4"><title>Brain-derived and SAA αSyn fibrils have distinct phosphorylation patterns</title><p>To conﬁrm the identity of the ﬁbrils imaged by TEM, we used immunogold with αSyn ﬁbril conformation speciﬁc (MJFR-14) and pS129-speciﬁc (anti-pαSyn) antibodies. Both brain-derived and SAA ﬁbrils from all four synucleinopathies were probed with MJFR-14, conﬁrming that the ﬁbrils were αSyn ﬁbrils (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). The brain-derived ﬁbrils were also strongly labeled with anti-pαSyn. Both antibodies, however, did not label the twisted brain-derived ﬁbrils from PD, PDD, and DLB (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). The SAA ﬁbrils from PD and MSA were not labeled with anti-pαSyn, but PD and MSA SAA ﬁbrils were weakly labeled (<xref ref-type="fig" rid="fig6">Figure 6A</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Brain-derived and seeding amplification assay (SAA) alpha-synuclein (αSyn) fibrils showed distinct phosphorylation patterns.</title><p>(<bold>A</bold>) Electron microscope image of brain-derived and SAA αSyn fibrils from Parkinson’s disease (PD), Parkinson’s disease with dementia (PDD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA) brains labeled with fibril conformation-specific (MJFR-14) and anti-pαSyn (pS129) antibodies. (<bold>B</bold>) The twisted αSyn fibrils from PD, PDD, and DLB brains were not labeled for MJFR-14 and pS129. Scale bar = 50 nm. (<bold>C,D</bold>) Semi-quantification of αSyn fibrils and pαSyn confirm the different patterns of αSyn phosphorylation between brain-derived and SAA αSyn fibrils. The amount of αSyn fibrils and pαSyn in (<bold>C</bold>) brain-derived and (<bold>D</bold>) SAA fibrils was determined using a slot blot. Two μg of proteins were filtered on a nitrocellulose membrane and probed with MJFR-14 and pS129 antibodies. The semi-quantitative measurement was done by averaging the measurements of three cases from each disease. Error bars indicate ± one standard deviation (SD). *p≤0.05.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Unedited slot blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92775-fig6-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Labelled unedited slot blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92775-fig6-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92775-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>pS129 immunogold transmission electron microscopy (TEM) images of the brain-derived alpha-synuclein (αSyn) fibrils.</title><p>The brain-derived αSyn fibrils were labeled with anti-pαSyn (pS129) and imaged at low magnification to compare the relative quantities of the pαSyn fibrils between the diseases. All three cases were imaged for each disease (<bold>A</bold>) Parkinson’s disease (PD), (<bold>B</bold>) Parkinson’s disease with dementia (PDD), (<bold>C</bold>) dementia with Lewy bodies (DLB), and (<bold>D</bold>) multiple system atrophy (MSA). The amount of pαSyn fibrils was examined using slot blots. Red arrows indicate labeled fibrils. Scale bar = 200 μm.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Unedited slot blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92775-fig6-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6s1sdata2"><label>Figure 6—figure supplement 1—source data 2.</label><caption><title>Labelled unedited slot blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92775-fig6-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92775-fig6-figsupp1-v1.tif"/></fig></fig-group><p>We performed a slot blot using identical antibodies to conﬁrm the immunogold-labeling results. On the slot blot, DLB brain-derived αSyn ﬁbrils showed the strongest signal with MJFR-14 and anti-pαSyn, followed by PDD, MSA, and PD (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Interestingly, the anti-pαSyn signal from the SAA ﬁbrils was markedly different from the brain-derived ﬁbrils. In parallel to the anti-pαSyn immunogold results (<xref ref-type="fig" rid="fig6">Figure 6A</xref>), PDD SAA ﬁbrils showed the highest anti-pαSyn signal (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). The DLB SAA ﬁbrils were also weakly phosphorylated, while those of PD and MSA were negative. Considering the absence of phosphorylated recombinant monomers in our SAA reaction, the phosphorylated αSyn must have transmitted from the seed brain-derived fibrils. Our results demonstrate that the brain-derived and SAA αSyn ﬁbrils display different patterns of S129 phosphorylation.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><sec id="s3-1"><title>Strain-like properties of the brain-derived αSyn fibrils from different synucleinopathies</title><p>Findings in this study provide evidence of distinct ‘strain-like’ properties of the brain-derived αSyn ﬁbrils from different synucleinopathies. First, faster seeding kinetics were observed in the brain-derived αSyn ﬁbrils from PDD and DLB than those from PD and MSA, suggesting a distinct ‘strain’ characterized by an aggressive seeding capacity. In contrast, those from PD and MSA are discrete ‘strains’ with milder seeding capacity.</p><p>When analysing the seeding kinetics, the different disease durations of our selected cases must be noted. In particular, our PDD cases had longer disease duration than PD, although both shared the same Braak stage 6. The Braak staging, however, only represents the distribution of LB pathology and fails to consider the load of LBs. We have shown that PDD brains showed higher LB load in the entorhinal cortex compared to PD brains. Thus, a higher accumulation of fibrils in PDD brains might have resulted in faster seeding kinetics. Nevertheless, our DLB cases had shorter disease duration than PDD, but the comparable burden of LBs and both diseases demonstrated similar seeding kinetics. Thus, the differential seeding kinetics is likely to result from strain properties or burden of pathology rather than disease duration.</p><p>Previous studies of αSyn SAA with CSF showed that PD and MSA could be distinguished using <inline-formula><mml:math id="inf4"><mml:msub><mml:mi>T</mml:mi><mml:mn>50</mml:mn></mml:msub></mml:math></inline-formula>, <inline-formula><mml:math id="inf5"><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mtext/><mml:mi>MAX</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> (<xref ref-type="bibr" rid="bib42">Poggiolini et al., 2022</xref>), and <inline-formula><mml:math id="inf6"><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mtext/><mml:mi>MAX</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> (<xref ref-type="bibr" rid="bib49">Shahnawaz et al., 2020</xref>; <xref ref-type="bibr" rid="bib48">Shahnawaz et al., 2017</xref>). However, in our αSyn SAA with brain-derived ﬁbrils, the same parameters cannot distinguish between PD and MSA. Differences in the ﬁndings are likely to arise from the type of seeds. An unprocessed CSF would likely comprise distinct and different concentrations of αSyn species. Moreover, the choice of biosample (CSF, olfactory mucosa, skin) significantly affects the outcome of seeding kinetics (<xref ref-type="bibr" rid="bib11">Chahine et al., 2020</xref>). By isolating the brain-derived αSyn fibrils, we could study the seeding kinetics of the fibrils themselves and, as a result, better understand their distinct intrinsic seeding properties.</p><p>Interestingly, one healthy control case (HC 2) showed amplification towards the end of the SAA reaction. The subject had Braak αSyn stage 0, suggesting the absence of incidental Lewy bodies. Previously, positive seeding activities have been detected in HCs (<xref ref-type="bibr" rid="bib25">Han et al., 2020</xref>). The exact cause of this observation is unclear, but the long reaction time might have contributed to the aggregation. SAA studies have shown that their HCs remain negative at 48–60 hr (<xref ref-type="bibr" rid="bib21">Groveman et al., 2018</xref>; <xref ref-type="bibr" rid="bib6">Bargar et al., 2021</xref>). Our HCs were negative at these times and only started to aggregate from 80 hr.</p><p>Next, examining the phosphorylated brain-derived αSyn fibrils (pαSyn), we demonstrate a possible correlation between the amount of pαSyn and rapid seeding kinetics. Studies have shown that pαSyn enhances αSyn aggregation in vitro (SH-SY5Y cells) and in vivo (rodent models) (<xref ref-type="bibr" rid="bib51">Smith et al., 2005</xref>; <xref ref-type="bibr" rid="bib27">Karampetsou et al., 2017</xref>). However, contradicting findings have also been reported, suggesting a neuroprotective role of pαSyn (<xref ref-type="bibr" rid="bib34">Ma et al., 2016</xref>; <xref ref-type="bibr" rid="bib19">Ghanem et al., 2022</xref>). Although the biological role of pαSyn is unclear, we report that a higher amount of pαSyn may contribute to the more aggressive seeding kinetics observed in PDD and DLB brain-derived αSyn fibrils than those of PD and MSA.</p><p>Further evidence of ‘strain-like’ property was exhibited by the distinct biochemical profiles of the brain-derived αSyn fibrils from different synucleinopathies. The brain-derived αSyn ﬁbrils from PD and MSA were more susceptible to GndHCl denaturation than PDD and DLB, indicating conformational instability of PD and MSA brain-derived αSyn fibrils. Nevertheless, it must be noted that the rapid denaturation of PD fibrils might be due to a low concentration of αSyn fibrils, as demonstrated by a lower Lewy pathology load in the entorhinal cortex. A previous study also showed that human brain-derived αSyn ﬁbrils from DLB were more stable than MSA by using GdnHCl treatment (<xref ref-type="bibr" rid="bib29">Lau et al., 2020</xref>). Interestingly, the less stable MSA fibrils propagated faster in TgM83 mice than the more stable DLB fibrils. Such inverse correlation between conformational stability and disease propagation has been characterized in prion disease (<xref ref-type="bibr" rid="bib31">Legname et al., 2006</xref>). Therefore, our findings on the differential conformational stability could reflect the strain-specific characteristics of αSyn fibrils. Subsequently, it could be related to the fast disease progression of MSA compared to PDD and DLB.</p><p>Subsequently, by assessing the PK-resistance of the αSyn ﬁbrils, we illustrate further the molecular diversity of αSyn fibrils. The sizes of the low MW PK-resistant fragments differed between diseases and cases within each disease. These distinct PK-resistant peptides suggest the presence of conformational variants indicative of αSyn ﬁbrillar strains within a single disease entity. Similarly, Guo and colleagues reported evidence of distinct αSyn ﬁbrillar conformers in different PDD patients’ brains (<xref ref-type="bibr" rid="bib23">Guo et al., 2013</xref>). Our group has also shown different SAA kinetics in the CSF samples of PD patients divided into four different subtypes based on their baseline and progressive motor and non-motor symptoms (<xref ref-type="bibr" rid="bib30">Lawton et al., 2018</xref>), suggesting αSyn strain heterogeneity within the same disease (<xref ref-type="bibr" rid="bib42">Poggiolini et al., 2022</xref>). Finally, unlike PDD and DLB, MSA αSyn ﬁbrils gradually disappeared upon PK treatment without being digested into small fragments. The lack of PK-resistant peptides in MSA indicate a readily digestible property of MSA αSyn ﬁbrils. Together with its conformational instability, these biochemical properties might indicate a specific αSyn strain in MSA.</p><p>Interestingly, MSA fibrils also showed distinct structural features compared to those from PD, PDD, and DLB. The fibrils from MSA were predominantly ‘straight’, and those from PD, PDD, and DLB were ‘straight’ and ‘twisted.’ While the ‘straight’ brain-derived fibrils were densely decorated with MJFR-14 and anti-pαSyn antibodies, confirming their identity as a phosphorylated αSyn fibril, the ‘twisted’ fibrils were not recognised by these proteins. Similarly, Spillantini and colleagues also reported a finding of ‘twisted’ fibril from the cingulate cortex of a DLB brain with no labeling by the αSyn-specific antibody (<xref ref-type="bibr" rid="bib53">Spillantini et al., 1998</xref>). Further ultrastructure analysis is essential to reveals the identity of the unlabeled twisted fibrils.</p><p>The methodological limitations of the structural characterisation in this study should be considered. Cryo-electron microscope (EM) ultrastructure revealed the twisted structures of the MSA brain-derived αSyn ﬁbrils and single twisted protofilament structures in PD, PDD, and DLB brains (<xref ref-type="bibr" rid="bib65">Yang et al., 2022</xref>). Our TEM structures may differ due to the selection of different brain regions compared to those used in the literature and the limitation of the resolving power of TEM. Future cryo-EM structural studies of αSyn fibrils from not only different synucleinopathies but also different brain regions and subtypes of PD are required. Accumulating evidence already suggests the presence of distinct biochemical properties among clinical and genetic subtypes of PD (<xref ref-type="bibr" rid="bib42">Poggiolini et al., 2022</xref>; <xref ref-type="bibr" rid="bib50">Siderowf et al., 2023</xref>). Thus, it is essential to continue investigating the molecular profiles to understand the diversity of αSyn conformers and their role in pathogenesis.</p></sec><sec id="s3-2"><title>Distinct biophysical properties between brain-derived and SAA fibrils</title><p>In order to assess whether the SAA fibrils truly replicate the brain-derived fibrils (the seed), we compared the biophysical characteristics of the brain-derived αSyn ﬁbrils and their respective SAA fibrils. First, by examining the resistance to GdnHCl and PK digestion, we illustrated a prominent biochemical difference between the brain-derived and SAA ﬁbrils. High concentrations (4–5 M) of GdnHCl completely denatured the brain-derived ﬁbrils, whilst SAA ﬁbrils were still resistant. This indicates that the SAA fibrils are more stable and PK-resistant than their respective brain-derived fibrils. Furthermore, the SAA ﬁbrils from all four synucleinopathies had identical patterns of PK resistance. The SAA amplifies fibrils with uniform biochemical features, losing the intrinsic properties of the original seed fibril and failing to replicate the biochemical properties of the original brain-derived fibrils.</p><p>The differences in biochemical stability might arise from the distinct distribution of the fibrils. SAA ﬁbrils were clustered in negative-stain TEM, whereas the brain-derived ﬁbrils were distributed in single ﬁlaments (<xref ref-type="fig" rid="fig5">Figure 5</xref>). Also, this study used a PIPES-based buffer to amplify the SAA ﬁbrils (<xref ref-type="bibr" rid="bib42">Poggiolini et al., 2022</xref>). As the microenvironmental context of αSyn ampliﬁcation substantially affects the newly amplified ﬁbrils (<xref ref-type="bibr" rid="bib41">Peng et al., 2018</xref>; <xref ref-type="bibr" rid="bib24">Gustavsson et al., 2021</xref>), the artiﬁcial in vitro environment can favor the formation of speciﬁc three-dimensional structures that are more conformationally stable.</p><p>Next, we showed that brain-derived ﬁbrils display a mixture of straight and twisted structures, while SAA ﬁbrils have a uniﬁed morphology: straight (PD, PDD, DLB) or twisted (MSA). This was an unexpected finding, as the conformational stability patterns were identical across all SAA fibrils. Here, technical limitations exist where the conformational stability was assessed using a single antibody targeting the 91–99 region of αSyn. A future study could employ multiple antibodies targeting the N- and C-terminus to further understand the relations between conformational stability and fibril morphology.</p><p>The striking structural difference may be due to a dominant seeding ﬁbril within the mixture of brain-derived ﬁbrils. Interestingly, straight fibrils were dominant in MSA brains, but the corresponding SAA fibrils were twisted. The commonality of a particular structure in a fibrillar mixture may not be a determinant of a dominant seeding fibril. Other factors might contribute, such as metal ions (<xref ref-type="bibr" rid="bib56">Uversky et al., 2001</xref>) and post-translational modifications (PTMs), which also affect seeding efficiency (<xref ref-type="bibr" rid="bib5">Balana et al., 2023</xref>). Also, our PIPES-based SAA reaction buffer with 150 mM NaCl is likely to have influenced the SAA fibril structure. However, the discrete structure of the MSA SAA fibrils compared to those of PD, PDD, and DLB implies that a complex matrix of intrinsic factors within the brain-derived fraction impacts seeding amplification and the resulting fibrillar structure.</p><p>A recent cryo-EM analysis of the MSA brain-derived and SAA ﬁbrils revealed striking structural differences (<xref ref-type="bibr" rid="bib47">Schweighauser et al., 2020</xref>; <xref ref-type="bibr" rid="bib33">Lövestam et al., 2021</xref>). A few significant differences included the protofilament fold, the inter-protofilament interface, and the geometry of specific residues that shape the hydrophobic core. As the TEM has restricted resolution, future cryo-EM analyses are imperative to connect the structure to the disease heterogeneity and progression.</p><p>Lastly, we investigated the differences in the phosphorylation level between the brain-derived and SAA αSyn ﬁbrils to identify differences in the PTM patterns. The brain-derived fibrils generally showed a higher phosphorylation level than the SAA fibrils. PDD and DLB SAA fibrils were weakly phosphorylated and decorated with pαSyn immunogold labels at the rare end of the fibrils (<xref ref-type="fig" rid="fig6">Figure 6</xref>). Combining these ﬁndings, we can argue the possibility that the SAA ﬁbrils extended from pαSyn species dissociated from the brain-derived ﬁbrils. Therefore, the amount of initial pαSyn ﬁbrils in the seed might be a critical determinant of the phosphorylation state of the resulting SAA ﬁbrils.</p><p>The dissimilarity observed in the brain-derived and SAA fibrils might result from the RT-QuIC methodology. For instance, prion studies reported that RT-QuIC end-products are non-infectious (<xref ref-type="bibr" rid="bib13">Coysh and Mead, 2022</xref>). On the other hand, PMCA prion end-products are infectious in vitro and in vivo and maintain strain-specific properties (<xref ref-type="bibr" rid="bib10">Castilla et al., 2005</xref>). This indicates the limitation of RT-QuIC in reproducing the toxicity of the source seeds as it loses biological information. Therefore, the biophysical differences between the brain-derived and SAA fibrils might result from the limitations of the RT-QuIC methodology.</p><p>Studies have explored the pathogenicity of brain-derived αSyn ﬁbrils in vitro using primary neurons, oligodendrocytes, and HEK cell lines expressing mutated αSyn (<xref ref-type="bibr" rid="bib60">Woerman et al., 2018a</xref>; <xref ref-type="bibr" rid="bib41">Peng et al., 2018</xref>; <xref ref-type="bibr" rid="bib59">Woerman et al., 2015</xref>; <xref ref-type="bibr" rid="bib64">Yamasaki et al., 2019</xref>). Moreover, similar pathological characterization has been done in different mouse models (<xref ref-type="bibr" rid="bib29">Lau et al., 2020</xref>; <xref ref-type="bibr" rid="bib62">Woerman et al., 2019</xref>; <xref ref-type="bibr" rid="bib60">Woerman et al., 2018a</xref>; <xref ref-type="bibr" rid="bib43">Prusiner et al., 2015</xref>; <xref ref-type="bibr" rid="bib41">Peng et al., 2018</xref>; <xref ref-type="bibr" rid="bib36">Masuda-Suzukake et al., 2013</xref>; <xref ref-type="bibr" rid="bib58">Watts et al., 2013</xref>; <xref ref-type="bibr" rid="bib7">Bernis et al., 2015</xref>; <xref ref-type="bibr" rid="bib61">Woerman et al., 2018b</xref>; <xref ref-type="bibr" rid="bib63">Woerman et al., 2020</xref>). Interestingly, both in vitro and in vivo, MSA brain-derived αSyn induced signiﬁcant αSyn aggregation, whereas those from PD/PDD and DLB brains produced either no or low αSyn accumulation. Similar disease-speciﬁc patterns were also observed in SAA-ampliﬁed ﬁbrils (<xref ref-type="bibr" rid="bib49">Shahnawaz et al., 2020</xref>; <xref ref-type="bibr" rid="bib57">Van der Perren et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">Tanudjojo et al., 2021</xref>). In future studies, it would be crucial to examine the brain-derived and SAA ﬁbrils in comparison in cellular and mouse models for their pathological characteristics.</p><p>In summary, the distinct biochemical profiles and structures of the brain-derived αSyn ﬁbrils from different synucleinopathies provide supporting evidence of molecular diversity of brain-derived αSyn ﬁbrils among different synucleinopathies and individual patients. Moreover, the SAA fibrils failed to adopt the biochemical, structural, and PTM properties of the seed brain-derived αSyn ﬁbrils, which addresses a significant limitation of SAA in replicating the intrinsic biophysical properties of the seed fibrils. Therefore, our finding highlights the necessity of re-evaluating the SAA seeding mechanism and its capacity to generate disease-relevant αSyn ﬁbrils used in different in vitro and in vivo models. Furthermore, it remains essential to investigate the human-derived αSyn ﬁbrils in the different brain regions and in other peripheral sites to explore αSyn strains and how they may affect the progression of pathology. They also remain the most disease-specific fibrils used in cellular and animal models.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Patient collection</title><p>Brain tissues from patients with PD and PDD were obtained from the Parkinson’s UK Brain Bank (Imperial College London, UK) in accordance with approved protocols by the London Multicentre Research Ethics Committee. Brain tissues from patients with DLB, MSA, and HC subjects were collected from the Oxford Brain Bank (OBB, University of Oxford, UK) in accordance with approved protocols by the South Central - Oxford C Research Ethics Committee (ref 23/SC/0241). All participants had given prior written informed consent for the brain donation. Both brain banks comply with the requirements of the Human Tissue Act 2004 and the Codes of Practice set by the Human Tissue Authority (HTA licence numbers 12275 for the Imperial and 12217 for OBB). The clinico-pathological demographics of the patients and healthy controls are summarized in Table tab:<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-2"><title>Extraction of αSyn fibrils from the human brain</title><p>Sarkosyl insoluble αSyn fibril was extracted from the brains of PD (n=3), PDD (n=3), DLB (n=3), MSA (n=3) patients, and healthy controls (n=3). The entorhinal cortex was selected for PD, PDD, and DLB, and the striatum was selected for MSA. The extraction protocol was adapted from the method presented by Schweighauser and colleagues (<xref ref-type="bibr" rid="bib47">Schweighauser et al., 2020</xref>). Brain tissues (0.5 g) were homogenized in an extraction buffer of 10 mM Tris-HCl, 0.8 M NaCl, 10% sucrose, and 1 mM EGTA (pH 7.5). Sarkosyl was added to a final concentration of 2% and incubated for 30 min at 37°C. Homogenates were centrifuged at 10,000 g for 10 min at 4°C. The supernatants were centrifuged at 100,000 g for 60 min at 4°C. The pellet was washed, resuspended in 500 μl/g of extraction buffer, and centrifuged at 500 g for 1 min at 4°C. The resulting supernatants were diluted 1/3 in buffer consisting of 50 mM Tris-HCl, 0.15 M NaCl, 10% sucrose, and 0.2% sarkosyl (pH 7.5). The diluted supernatant was centrifuged at 100,000 g for 60 min at 4°C. The resulting pellet was washed and resuspended in 250 μl/g of 30 mM Tris-HCl (pH 7.5), being the sarkosyl-insoluble fraction. The protein concentration was determined using the bicinchoninic acid assay (BCA) (Thermo Scientific). The sarkosyl insoluble fraction was aliquoted and stored at –80°C.</p></sec><sec id="s4-3"><title>αSyn SAA</title><p>The brain-derived αSyn fibrils were diluted 1:1000 in 30 mM Tris-HCl (pH 7.5), and 2 μl was added to 98 μl of the reaction mixture consisting of 100 mM PIPES (pH 7), 150 mM NaCl, 0.1 mg/ml of recombinant αSyn (rPeptide) and 10 μM thioflavin-T (ThT) to a final reaction volume of 100 μl. Before use, the recombinant αSyn was filtered through a 100 kDa molecular weight cut-off (MWCO) filter. The reaction mixture was loaded onto a black 96-well plate with a clear bottom (Nalgene Nunc). The plate was sealed with a plate sealing film (Thermo Scientific) and incubated at 42°C in a BMG FLUOstar Omega plate reader for 100 hr with cycles of 1 min shaking (400 rpm double orbital) and 1 min rest. ThT fluorescence measurement (450 nm excitation and 480 nm emission) was taken every 30 min. Each sample was run in six replicates. The reaction end-products were ultracentrifuged at 100,000 g for 1 hr at 4°C and collected as SAA fibril.</p></sec><sec id="s4-4"><title>Conformational stability assay and immunoblotting</title><p>The brain-derived αSyn fibrils (10 μg) and SAA fibrils (1 μg) were treated with different GdnHCl concentrations (0–5 M) at 37°C for 1 hr on a thermoshaker (800 rpm). The reactions were stopped by reducing the GdnHCl concentration to 0.5 M. The fibrils were treated with 1 μg/ml of proteinase-K (PK) at 37°C for 30 min on a thermoshaker (500 rpm). Digested samples were collected using ultracentrifugation at 100,000 g, 4°C for 1 hr. Tricine sample buffer (Bio-Rad) was added to the samples and boiled at 95°C for 10 min. The samples were analyzed with 16.5% Tris-Tricine gels (Bio-Rad) and immunoblotted on nitrocellulose membranes (Amersham). Membranes were blocked with 5% skimmed milk in TBS-Tween and incubated with anti-αSyn clone 42 (BD Biosciences, 1:1000 dilution). In a slot blot, 2 μg of protein was immobilized on a nitrocellulose membrane (Amersham) by filtration using a slot blot apparatus (GE Healthcare). The membrane was blocked with 5% skimmed milk and probed with MJFR-14-6-4-2 (Abcam, 1:3000 dilution) and EP1536Y (Abcam, 1:1,000 dilution). The membranes were developed using an ECL western blot detection kit (Amersham). Semi-quantitative analysis of the slot blot data was performed using ImageJ.</p></sec><sec id="s4-5"><title>TEM and immunolabeling electron microscopy</title><p>Five μl of 0.5 μg brain-derived αSyn fibrils and 5 μl of SAA fibrils were applied to glow-discharged carbon grids (Agar Scientific, 300 mesh) and incubated for 2 min. The grid was washed with water for 10 s and negatively stained with 2% uranyl acetate for 10 s. Stained samples were imaged on an FEI Tecnai T12 microscope operated at 120 kV.</p><p>For immunolabeling, the fibrils were applied to glow-discharged carbon grids and blocked with a blocking buffer (0.2% fish gelatin in PBS). Then, the grid was incubated with antibodies targeting the phosphorylated αSyn (EP1536Y, Abcam, 1:20 dilution) and αSyn fibril conformer (MJFR-14-6-4-2, Abcam, 1:50 dilution). After washing with blocking buffer, the sample was incubated with goat anti-rabbit IgG coupled with 10 nm gold (Ab27234, Abcam) diluted 1:10 in the blocking buffer. Then, the grid was fixed with 0.1% glutaraldehyde in PBS. The samples were stained with 2% uranyl acetate for 30 s.</p></sec><sec id="s4-6"><title>Immunohistochemistry</title><p>Six µm-thick sections of formalin-ﬁxed paraﬃn-embedded (FFPE) human brain tissue sections were de-paraﬃnized in xylene (3x5 min) and rehydrated through decreasing concentration of industrial denatured alcohol (IDA) (100%, 100%, 90%, 70%; 5 min each) and subsequently in distilled water (5 min). For antigen retrieval, sections were treated with 70% formic acid for 15 min. The sections were then blocked with 3% H<sub>2</sub>O<sub>2</sub> for 20 min and with 10%fetal bovine serum (FBS) in PBS for 30 min. Sections were incubated with anti-αSyn clone 42 (BD Biosciences) diluted 1:1000 in 10%FBS overnight at 4°C. After washing with PBS (3×5 min), sections were incubated with Ms/Rb-HRP secondary antibody (Agilent Technologies) for 30 min at RT. Sections were developed with Dako DAB (Agilent Technologies) and counterstained with haematoxylin. Finally, sections were mounted to coverslips with DPX (Thermo Scientiﬁc).</p></sec><sec id="s4-7"><title>Statistical analysis</title><p>Mann-Whitney U test was used when comparing two independent groups. Independent Kruskal-Wallis Test was performed to compare more than three groups for SAA kinetic parameters <xref ref-type="fig" rid="fig2">Figure 2</xref>, ﬁbril dimensions (PD, PDD, DLB, and MSA) <xref ref-type="fig" rid="fig5">Figure 5</xref>, and the amount of phosphorylated αSyn ﬁbrils <xref ref-type="fig" rid="fig6">Figure 6</xref>. p-values &lt;0.05 were considered statistically signiﬁcant. All statistical analyses were performed using SPSS Statistics, Version 28.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing - original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Supervision, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Supervision, Funding acquisition, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Brain tissues from patients with PD and PDD were obtained from the Parkinson's UK Brain Bank (Imperial College London, UK) in accordance with approved protocols by the London Multicentre Research Ethics Committee. Brain tissues from patients with DLB, MSA and healthy controls were collected from the Oxford Brain Bank (OBB, University of Oxford, UK) in accordance with approved protocols by the South Central - Oxford C Research Ethics Committee (ref 23/SC/0241). All participants had given prior written informed consent for the brain donation. Both brain banks comply with the requirements of the Human Tissue Act 2004 and the Codes of Practice set by the Human Tissue Authority (HTA licence numbers 12275 for the Imperial and 12217 for OBB).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Clinicopathological summary of the patients included in this study.</title><p>The table summarizes the clinical and pathological reports of the patients included in this study. PD, Parkinson’s disease; PDD, Parkinson’s disease with dementia; DLB, dementia with Lewy body; MSA, multiple system atrophy; HC, healthy control; ECtx, entorhinal cortex; BG, basal ganglia; M, male; F, female; AD, Alzheimer’s disease; CVD, cardiovascular disease; and alpha-synuclein (αSyn).</p></caption><media xlink:href="elife-92775-supp1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-92775-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The study did not generate any novel datasets.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank all the patients and their families for the valuable brain donations for research. We also want to thank Dr. Errin Johnson and the Oxford bioimaging facility for providing access and training for transmission electron microscopy and assisting with acquiring the imaging data. We acknowledge Dr. Alan King Lun Liu for helping us with the case selection and analysis of the clinical summary of the patients. We acknowledge the Oxford Brain Bank, supported by Brains for Dementia Research (BDR) (Alzheimer Society and Alzheimer Research UK) and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). LP is supported by the GSK-Institute of Molecular &amp; Computational Medicine, NIHR Oxford BRC, Parkinson Foundation, the Michael J Fox Foundation, the Galen and Hilary Weston Foundation, and the National Institute of Health. LC is supported by NIHR Oxford BRC.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alafuzoff</surname><given-names>I</given-names></name><name><surname>Arzberger</surname><given-names>T</given-names></name><name><surname>Al-Sarraj</surname><given-names>S</given-names></name><name><surname>Bodi</surname><given-names>I</given-names></name><name><surname>Bogdanovic</surname><given-names>N</given-names></name><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Bugiani</surname><given-names>O</given-names></name><name><surname>Del-Tredici</surname><given-names>K</given-names></name><name><surname>Ferrer</surname><given-names>I</given-names></name><name><surname>Gelpi</surname><given-names>E</given-names></name><name><surname>Giaccone</surname><given-names>G</given-names></name><name><surname>Graeber</surname><given-names>MB</given-names></name><name><surname>Ince</surname><given-names>P</given-names></name><name><surname>Kamphorst</surname><given-names>W</given-names></name><name><surname>King</surname><given-names>A</given-names></name><name><surname>Korkolopoulou</surname><given-names>P</given-names></name><name><surname>Kovács</surname><given-names>GG</given-names></name><name><surname>Larionov</surname><given-names>S</given-names></name><name><surname>Meyronet</surname><given-names>D</given-names></name><name><surname>Monoranu</surname><given-names>C</given-names></name><name><surname>Parchi</surname><given-names>P</given-names></name><name><surname>Patsouris</surname><given-names>E</given-names></name><name><surname>Roggendorf</surname><given-names>W</given-names></name><name><surname>Seilhean</surname><given-names>D</given-names></name><name><surname>Tagliavini</surname><given-names>F</given-names></name><name><surname>Stadelmann</surname><given-names>C</given-names></name><name><surname>Streichenberger</surname><given-names>N</given-names></name><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>Wharton</surname><given-names>SB</given-names></name><name><surname>Kretzschmar</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Staging of neurofibrillary pathology in Alzheimer’s disease: A study of the BrainNet Europe Consortium</article-title><source>Brain Pathology</source><volume>18</volume><fpage>484</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.2008.00147.x</pub-id><pub-id pub-id-type="pmid">18371174</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alafuzoff</surname><given-names>I</given-names></name><name><surname>Ince</surname><given-names>PG</given-names></name><name><surname>Arzberger</surname><given-names>T</given-names></name><name><surname>Al-Sarraj</surname><given-names>S</given-names></name><name><surname>Bell</surname><given-names>J</given-names></name><name><surname>Bodi</surname><given-names>I</given-names></name><name><surname>Bogdanovic</surname><given-names>N</given-names></name><name><surname>Bugiani</surname><given-names>O</given-names></name><name><surname>Ferrer</surname><given-names>I</given-names></name><name><surname>Gelpi</surname><given-names>E</given-names></name><name><surname>Gentleman</surname><given-names>S</given-names></name><name><surname>Giaccone</surname><given-names>G</given-names></name><name><surname>Ironside</surname><given-names>JW</given-names></name><name><surname>Kavantzas</surname><given-names>N</given-names></name><name><surname>King</surname><given-names>A</given-names></name><name><surname>Korkolopoulou</surname><given-names>P</given-names></name><name><surname>Kovács</surname><given-names>GG</given-names></name><name><surname>Meyronet</surname><given-names>D</given-names></name><name><surname>Monoranu</surname><given-names>C</given-names></name><name><surname>Parchi</surname><given-names>P</given-names></name><name><surname>Parkkinen</surname><given-names>L</given-names></name><name><surname>Patsouris</surname><given-names>E</given-names></name><name><surname>Roggendorf</surname><given-names>W</given-names></name><name><surname>Rozemuller</surname><given-names>A</given-names></name><name><surname>Stadelmann-Nessler</surname><given-names>C</given-names></name><name><surname>Streichenberger</surname><given-names>N</given-names></name><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>Kretzschmar</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Staging/typing of Lewy body related alpha-synuclein pathology: A study of the BrainNet Europe Consortium</article-title><source>Acta Neuropathologica</source><volume>117</volume><fpage>635</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1007/s00401-009-0523-2</pub-id><pub-id pub-id-type="pmid">19330340</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altay</surname><given-names>MF</given-names></name><name><surname>Liu</surname><given-names>AKL</given-names></name><name><surname>Holton</surname><given-names>JL</given-names></name><name><surname>Parkkinen</surname><given-names>L</given-names></name><name><surname>Lashuel</surname><given-names>HA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders</article-title><source>Acta Neuropathologica Communications</source><volume>10</volume><elocation-id>163</elocation-id><pub-id pub-id-type="doi">10.1186/s40478-022-01468-8</pub-id><pub-id pub-id-type="pmid">36371251</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayers</surname><given-names>JI</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Monteiro</surname><given-names>O</given-names></name><name><surname>Woerman</surname><given-names>AL</given-names></name><name><surname>Lazar</surname><given-names>AA</given-names></name><name><surname>Condello</surname><given-names>C</given-names></name><name><surname>Paras</surname><given-names>NA</given-names></name><name><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Different α-synuclein prion strains cause dementia with Lewy bodies and multiple system atrophy</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2113489119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2113489119</pub-id><pub-id pub-id-type="pmid">35115402</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Balana</surname><given-names>AT</given-names></name><name><surname>Mahul-Mellier</surname><given-names>AL</given-names></name><name><surname>Nguyen</surname><given-names>BA</given-names></name><name><surname>Horvath</surname><given-names>M</given-names></name><name><surname>Javed</surname><given-names>A</given-names></name><name><surname>Hard</surname><given-names>ER</given-names></name><name><surname>Jasiqi</surname><given-names>Y</given-names></name><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Afrin</surname><given-names>S</given-names></name><name><surname>Pedretti</surname><given-names>R</given-names></name><name><surname>Singh</surname><given-names>V</given-names></name><name><surname>Lee</surname><given-names>VMY</given-names></name><name><surname>Luk</surname><given-names>KC</given-names></name><name><surname>Saelices</surname><given-names>L</given-names></name><name><surname>Lashuel</surname><given-names>HA</given-names></name><name><surname>Pratt</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>O-GlcNAc Modification Forces the Formation of an α-Synuclein Amyloid-Strain with Notably Diminished Seeding Activity and Pathology</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2023.03.07.531573</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bargar</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Gunzler</surname><given-names>SA</given-names></name><name><surname>LeFevre</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Lerner</surname><given-names>AJ</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Tatsuoka</surname><given-names>C</given-names></name><name><surname>Appleby</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Haroutunian</surname><given-names>V</given-names></name><name><surname>Zou</surname><given-names>W-Q</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson’s disease and dementia with Lewy bodies</article-title><source>Acta Neuropathologica Communications</source><volume>9</volume><elocation-id>62</elocation-id><pub-id pub-id-type="doi">10.1186/s40478-021-01175-w</pub-id><pub-id pub-id-type="pmid">33827706</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernis</surname><given-names>ME</given-names></name><name><surname>Babila</surname><given-names>JT</given-names></name><name><surname>Breid</surname><given-names>S</given-names></name><name><surname>Wüsten</surname><given-names>KA</given-names></name><name><surname>Wüllner</surname><given-names>U</given-names></name><name><surname>Tamgüney</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein</article-title><source>Acta Neuropathologica Communications</source><volume>3</volume><elocation-id>75</elocation-id><pub-id pub-id-type="doi">10.1186/s40478-015-0254-7</pub-id><pub-id pub-id-type="pmid">26612754</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousset</surname><given-names>L</given-names></name><name><surname>Pieri</surname><given-names>L</given-names></name><name><surname>Ruiz-Arlandis</surname><given-names>G</given-names></name><name><surname>Gath</surname><given-names>J</given-names></name><name><surname>Jensen</surname><given-names>PH</given-names></name><name><surname>Habenstein</surname><given-names>B</given-names></name><name><surname>Madiona</surname><given-names>K</given-names></name><name><surname>Olieric</surname><given-names>V</given-names></name><name><surname>Böckmann</surname><given-names>A</given-names></name><name><surname>Meier</surname><given-names>BH</given-names></name><name><surname>Melki</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Structural and functional characterization of two alpha-synuclein strains</article-title><source>Nature Communications</source><volume>4</volume><elocation-id>2575</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms3575</pub-id><pub-id pub-id-type="pmid">24108358</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><name><surname>Rüb</surname><given-names>U</given-names></name><name><surname>de Vos</surname><given-names>RAI</given-names></name><name><surname>Jansen Steur</surname><given-names>ENH</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Staging of brain pathology related to sporadic Parkinson’s disease</article-title><source>Neurobiology of Aging</source><volume>24</volume><fpage>197</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1016/s0197-4580(02)00065-9</pub-id><pub-id pub-id-type="pmid">12498954</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castilla</surname><given-names>J</given-names></name><name><surname>Saá</surname><given-names>P</given-names></name><name><surname>Hetz</surname><given-names>C</given-names></name><name><surname>Soto</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>In vitro generation of infectious scrapie prions</article-title><source>Cell</source><volume>121</volume><fpage>195</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.02.011</pub-id><pub-id pub-id-type="pmid">15851027</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chahine</surname><given-names>LM</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Brumm</surname><given-names>MC</given-names></name><name><surname>Adler</surname><given-names>CH</given-names></name><name><surname>Coffey</surname><given-names>CS</given-names></name><name><surname>Mosovsky</surname><given-names>S</given-names></name><name><surname>Caspell-Garcia</surname><given-names>C</given-names></name><name><surname>Serrano</surname><given-names>GE</given-names></name><name><surname>Munoz</surname><given-names>DG</given-names></name><name><surname>Crary</surname><given-names>JF</given-names></name><name><surname>Jennings</surname><given-names>D</given-names></name><name><surname>Taylor</surname><given-names>P</given-names></name><name><surname>Foroud</surname><given-names>T</given-names></name><name><surname>Arnedo</surname><given-names>V</given-names></name><name><surname>Kopil</surname><given-names>CM</given-names></name><name><surname>Riley</surname><given-names>L</given-names></name><name><surname>Dave</surname><given-names>KD</given-names></name><name><surname>Mollenhauer</surname><given-names>B</given-names></name><collab>Systemic Synuclein Sampling Study</collab></person-group><year iso-8601-date="2020">2020</year><article-title>In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease</article-title><source>Neurology</source><volume>95</volume><fpage>e1267</fpage><lpage>e1284</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000010404</pub-id><pub-id pub-id-type="pmid">32747521</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Concha-Marambio</surname><given-names>L</given-names></name><name><surname>Pritzkow</surname><given-names>S</given-names></name><name><surname>Shahnawaz</surname><given-names>M</given-names></name><name><surname>Farris</surname><given-names>CM</given-names></name><name><surname>Soto</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid</article-title><source>Nature Protocols</source><volume>18</volume><fpage>1179</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.1038/s41596-022-00787-3</pub-id><pub-id pub-id-type="pmid">36653527</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coysh</surname><given-names>T</given-names></name><name><surname>Mead</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The future of seed amplification assays and clinical trials</article-title><source>Frontiers in Aging Neuroscience</source><volume>14</volume><elocation-id>872629</elocation-id><pub-id pub-id-type="doi">10.3389/fnagi.2022.872629</pub-id><pub-id pub-id-type="pmid">35813946</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniel</surname><given-names>SE</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Parkinson’s disease society brain bank, london: overview and research</article-title><source>Journal of Neural Transmission. Supplementum</source><volume>39</volume><fpage>165</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">8360656</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Burn</surname><given-names>D</given-names></name><name><surname>Goetz</surname><given-names>C</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Brown</surname><given-names>RG</given-names></name><name><surname>Broe</surname><given-names>GA</given-names></name><name><surname>Dickson</surname><given-names>D</given-names></name><name><surname>Duyckaerts</surname><given-names>C</given-names></name><name><surname>Cummings</surname><given-names>J</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name><name><surname>Korczyn</surname><given-names>A</given-names></name><name><surname>Lees</surname><given-names>A</given-names></name><name><surname>Levy</surname><given-names>R</given-names></name><name><surname>Litvan</surname><given-names>I</given-names></name><name><surname>Mizuno</surname><given-names>Y</given-names></name><name><surname>McKeith</surname><given-names>IG</given-names></name><name><surname>Olanow</surname><given-names>CW</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>Sampaio</surname><given-names>C</given-names></name><name><surname>Tolosa</surname><given-names>E</given-names></name><name><surname>Emre</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force</article-title><source>Movement Disorders</source><volume>22</volume><fpage>2314</fpage><lpage>2324</lpage><pub-id pub-id-type="doi">10.1002/mds.21844</pub-id><pub-id pub-id-type="pmid">18098298</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fairfoul</surname><given-names>G</given-names></name><name><surname>McGuire</surname><given-names>LI</given-names></name><name><surname>Pal</surname><given-names>S</given-names></name><name><surname>Ironside</surname><given-names>JW</given-names></name><name><surname>Neumann</surname><given-names>J</given-names></name><name><surname>Christie</surname><given-names>S</given-names></name><name><surname>Joachim</surname><given-names>C</given-names></name><name><surname>Esiri</surname><given-names>M</given-names></name><name><surname>Evetts</surname><given-names>SG</given-names></name><name><surname>Rolinski</surname><given-names>M</given-names></name><name><surname>Baig</surname><given-names>F</given-names></name><name><surname>Ruffmann</surname><given-names>C</given-names></name><name><surname>Wade-Martins</surname><given-names>R</given-names></name><name><surname>Hu</surname><given-names>MTM</given-names></name><name><surname>Parkkinen</surname><given-names>L</given-names></name><name><surname>Green</surname><given-names>AJE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies</article-title><source>Annals of Clinical and Translational Neurology</source><volume>3</volume><fpage>812</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1002/acn3.338</pub-id><pub-id pub-id-type="pmid">27752516</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Forno</surname><given-names>LS</given-names></name></person-group><year iso-8601-date="1988">1988</year><chapter-title>The neuropathology of parkinson’s disease</chapter-title><person-group person-group-type="editor"><name><surname>Forno</surname><given-names>LS</given-names></name></person-group><source>Progress in Parkinson Research</source><publisher-name>Springer</publisher-name><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1007/978-1-4613-0759-4_2</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frieg</surname><given-names>B</given-names></name><name><surname>Geraets</surname><given-names>JA</given-names></name><name><surname>Strohäker</surname><given-names>T</given-names></name><name><surname>Dienemann</surname><given-names>C</given-names></name><name><surname>Mavroeidi</surname><given-names>P</given-names></name><name><surname>Jung</surname><given-names>BC</given-names></name><name><surname>Kim</surname><given-names>WS</given-names></name><name><surname>Lee</surname><given-names>S-J</given-names></name><name><surname>Xilouri</surname><given-names>M</given-names></name><name><surname>Zweckstetter</surname><given-names>M</given-names></name><name><surname>Schröder</surname><given-names>GF</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Quaternary structure of patient-homogenate amplified α-synuclein fibrils modulates seeding of endogenous α-synuclein</article-title><source>Communications Biology</source><volume>5</volume><elocation-id>1040</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-022-03948-y</pub-id><pub-id pub-id-type="pmid">36180728</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghanem</surname><given-names>SS</given-names></name><name><surname>Majbour</surname><given-names>NK</given-names></name><name><surname>Vaikath</surname><given-names>NN</given-names></name><name><surname>Ardah</surname><given-names>MT</given-names></name><name><surname>Erskine</surname><given-names>D</given-names></name><name><surname>Jensen</surname><given-names>NM</given-names></name><name><surname>Fayyad</surname><given-names>M</given-names></name><name><surname>Sudhakaran</surname><given-names>IP</given-names></name><name><surname>Vasili</surname><given-names>E</given-names></name><name><surname>Melachroinou</surname><given-names>K</given-names></name><name><surname>Abdi</surname><given-names>IY</given-names></name><name><surname>Poggiolini</surname><given-names>I</given-names></name><name><surname>Santos</surname><given-names>P</given-names></name><name><surname>Dorn</surname><given-names>A</given-names></name><name><surname>Carloni</surname><given-names>P</given-names></name><name><surname>Vekrellis</surname><given-names>K</given-names></name><name><surname>Attems</surname><given-names>J</given-names></name><name><surname>McKeith</surname><given-names>I</given-names></name><name><surname>Outeiro</surname><given-names>TF</given-names></name><name><surname>Jensen</surname><given-names>PH</given-names></name><name><surname>El-Agnaf</surname><given-names>OMA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2109617119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2109617119</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilman</surname><given-names>S</given-names></name><name><surname>Low</surname><given-names>P</given-names></name><name><surname>Quinn</surname><given-names>N</given-names></name><name><surname>Albanese</surname><given-names>A</given-names></name><name><surname>Ben-Shlomo</surname><given-names>Y</given-names></name><name><surname>Fowler</surname><given-names>C</given-names></name><name><surname>Kaufmann</surname><given-names>H</given-names></name><name><surname>Klockgether</surname><given-names>T</given-names></name><name><surname>Lang</surname><given-names>A</given-names></name><name><surname>Lantos</surname><given-names>P</given-names></name><name><surname>Litvan</surname><given-names>I</given-names></name><name><surname>Mathias</surname><given-names>C</given-names></name><name><surname>Oliver</surname><given-names>E</given-names></name><name><surname>Robertson</surname><given-names>D</given-names></name><name><surname>Schatz</surname><given-names>I</given-names></name><name><surname>Wenning</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Consensus statement on the diagnosis of multiple system atrophy</article-title><source>Clinical Autonomic Research</source><volume>8</volume><fpage>359</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1007/BF02309628</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groveman</surname><given-names>BR</given-names></name><name><surname>Orrù</surname><given-names>CD</given-names></name><name><surname>Hughson</surname><given-names>AG</given-names></name><name><surname>Raymond</surname><given-names>LD</given-names></name><name><surname>Zanusso</surname><given-names>G</given-names></name><name><surname>Ghetti</surname><given-names>B</given-names></name><name><surname>Campbell</surname><given-names>KJ</given-names></name><name><surname>Safar</surname><given-names>J</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Caughey</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC</article-title><source>Acta Neuropathologica Communications</source><volume>6</volume><elocation-id>7</elocation-id><pub-id pub-id-type="doi">10.1186/s40478-018-0508-2</pub-id><pub-id pub-id-type="pmid">29422107</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guerrero-Ferreira</surname><given-names>R</given-names></name><name><surname>Taylor</surname><given-names>NM</given-names></name><name><surname>Arteni</surname><given-names>A-A</given-names></name><name><surname>Kumari</surname><given-names>P</given-names></name><name><surname>Mona</surname><given-names>D</given-names></name><name><surname>Ringler</surname><given-names>P</given-names></name><name><surname>Britschgi</surname><given-names>M</given-names></name><name><surname>Lauer</surname><given-names>ME</given-names></name><name><surname>Makky</surname><given-names>A</given-names></name><name><surname>Verasdonck</surname><given-names>J</given-names></name><name><surname>Riek</surname><given-names>R</given-names></name><name><surname>Melki</surname><given-names>R</given-names></name><name><surname>Meier</surname><given-names>BH</given-names></name><name><surname>Böckmann</surname><given-names>A</given-names></name><name><surname>Bousset</surname><given-names>L</given-names></name><name><surname>Stahlberg</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy</article-title><source>eLife</source><volume>8</volume><elocation-id>e48907</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.48907</pub-id><pub-id pub-id-type="pmid">31815671</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>JL</given-names></name><name><surname>Covell</surname><given-names>DJ</given-names></name><name><surname>Daniels</surname><given-names>JP</given-names></name><name><surname>Iba</surname><given-names>M</given-names></name><name><surname>Stieber</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Riddle</surname><given-names>DM</given-names></name><name><surname>Kwong</surname><given-names>LK</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>VMY</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Distinct α-synuclein strains differentially promote tau inclusions in neurons</article-title><source>Cell</source><volume>154</volume><fpage>103</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.05.057</pub-id><pub-id pub-id-type="pmid">23827677</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gustavsson</surname><given-names>N</given-names></name><name><surname>Savchenko</surname><given-names>E</given-names></name><name><surname>Klementieva</surname><given-names>O</given-names></name><name><surname>Roybon</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The intracellular milieu of Parkinson’s disease patient brain cells modulates alpha-synuclein protein aggregation</article-title><source>Acta Neuropathologica Communications</source><volume>9</volume><elocation-id>153</elocation-id><pub-id pub-id-type="doi">10.1186/s40478-021-01256-w</pub-id><pub-id pub-id-type="pmid">34530929</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>J-Y</given-names></name><name><surname>Jang</surname><given-names>H-S</given-names></name><name><surname>Green</surname><given-names>AJE</given-names></name><name><surname>Choi</surname><given-names>YP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>RT-QuIC-based detection of alpha-synuclein seeding activity in brains of dementia with Lewy Body patients and of a transgenic mouse model of synucleinopathy</article-title><source>Prion</source><volume>14</volume><fpage>88</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1080/19336896.2020.1724608</pub-id><pub-id pub-id-type="pmid">32041499</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holec</surname><given-names>SAM</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Oehler</surname><given-names>A</given-names></name><name><surname>Ooi</surname><given-names>FK</given-names></name><name><surname>Mordes</surname><given-names>DA</given-names></name><name><surname>Olson</surname><given-names>SH</given-names></name><name><surname>Prusiner</surname><given-names>SB</given-names></name><name><surname>Woerman</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Multiple system atrophy prions transmit neurological disease to mice expressing wild-type human α-synuclein</article-title><source>Acta Neuropathologica</source><volume>144</volume><fpage>677</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1007/s00401-022-02476-7</pub-id><pub-id pub-id-type="pmid">36018376</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karampetsou</surname><given-names>M</given-names></name><name><surname>Ardah</surname><given-names>MT</given-names></name><name><surname>Semitekolou</surname><given-names>M</given-names></name><name><surname>Polissidis</surname><given-names>A</given-names></name><name><surname>Samiotaki</surname><given-names>M</given-names></name><name><surname>Kalomoiri</surname><given-names>M</given-names></name><name><surname>Majbour</surname><given-names>N</given-names></name><name><surname>Xanthou</surname><given-names>G</given-names></name><name><surname>El-Agnaf</surname><given-names>OMA</given-names></name><name><surname>Vekrellis</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>16533</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-15813-8</pub-id><pub-id pub-id-type="pmid">29184069</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuzkina</surname><given-names>A</given-names></name><name><surname>Bargar</surname><given-names>C</given-names></name><name><surname>Schmitt</surname><given-names>D</given-names></name><name><surname>Rößle</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Schubert</surname><given-names>AL</given-names></name><name><surname>Tatsuoka</surname><given-names>C</given-names></name><name><surname>Gunzler</surname><given-names>SA</given-names></name><name><surname>Zou</surname><given-names>WQ</given-names></name><name><surname>Volkmann</surname><given-names>J</given-names></name><name><surname>Sommer</surname><given-names>C</given-names></name><name><surname>Doppler</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Diagnostic value of skin RT-QuIC in Parkinson’s disease: a two-laboratory study</article-title><source>NPJ Parkinson’s Disease</source><volume>7</volume><elocation-id>99</elocation-id><pub-id pub-id-type="doi">10.1038/s41531-021-00242-2</pub-id><pub-id pub-id-type="pmid">34782640</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>A</given-names></name><name><surname>So</surname><given-names>RWL</given-names></name><name><surname>Lau</surname><given-names>HHC</given-names></name><name><surname>Sang</surname><given-names>JC</given-names></name><name><surname>Ruiz-Riquelme</surname><given-names>A</given-names></name><name><surname>Fleck</surname><given-names>SC</given-names></name><name><surname>Stuart</surname><given-names>E</given-names></name><name><surname>Menon</surname><given-names>S</given-names></name><name><surname>Visanji</surname><given-names>NP</given-names></name><name><surname>Meisl</surname><given-names>G</given-names></name><name><surname>Faidi</surname><given-names>R</given-names></name><name><surname>Marano</surname><given-names>MM</given-names></name><name><surname>Schmitt-Ulms</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Fraser</surname><given-names>PE</given-names></name><name><surname>Tandon</surname><given-names>A</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Wille</surname><given-names>H</given-names></name><name><surname>Ingelsson</surname><given-names>M</given-names></name><name><surname>Klenerman</surname><given-names>D</given-names></name><name><surname>Watts</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>α-Synuclein strains target distinct brain regions and cell types</article-title><source>Nature Neuroscience</source><volume>23</volume><fpage>21</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1038/s41593-019-0541-x</pub-id><pub-id pub-id-type="pmid">31792467</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawton</surname><given-names>M</given-names></name><name><surname>Ben-Shlomo</surname><given-names>Y</given-names></name><name><surname>May</surname><given-names>MT</given-names></name><name><surname>Baig</surname><given-names>F</given-names></name><name><surname>Barber</surname><given-names>TR</given-names></name><name><surname>Klein</surname><given-names>JC</given-names></name><name><surname>Swallow</surname><given-names>DMA</given-names></name><name><surname>Malek</surname><given-names>N</given-names></name><name><surname>Grosset</surname><given-names>KA</given-names></name><name><surname>Bajaj</surname><given-names>N</given-names></name><name><surname>Barker</surname><given-names>RA</given-names></name><name><surname>Williams</surname><given-names>N</given-names></name><name><surname>Burn</surname><given-names>DJ</given-names></name><name><surname>Foltynie</surname><given-names>T</given-names></name><name><surname>Morris</surname><given-names>HR</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name><name><surname>Grosset</surname><given-names>DG</given-names></name><name><surname>Hu</surname><given-names>MTM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression</article-title><source>Journal of Neurology, Neurosurgery &amp; Psychiatry</source><volume>89</volume><fpage>1279</fpage><lpage>1287</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2018-318337</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Legname</surname><given-names>G</given-names></name><name><surname>Nguyen</surname><given-names>HOB</given-names></name><name><surname>Peretz</surname><given-names>D</given-names></name><name><surname>Cohen</surname><given-names>FE</given-names></name><name><surname>DeArmond</surname><given-names>SJ</given-names></name><name><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes</article-title><source>PNAS</source><volume>103</volume><fpage>19105</fpage><lpage>19110</lpage><pub-id pub-id-type="doi">10.1073/pnas.0608970103</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Ge</surname><given-names>P</given-names></name><name><surname>Murray</surname><given-names>KA</given-names></name><name><surname>Sheth</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Nair</surname><given-names>G</given-names></name><name><surname>Sawaya</surname><given-names>MR</given-names></name><name><surname>Shin</surname><given-names>WS</given-names></name><name><surname>Boyer</surname><given-names>DR</given-names></name><name><surname>Ye</surname><given-names>S</given-names></name><name><surname>Eisenberg</surname><given-names>DS</given-names></name><name><surname>Zhou</surname><given-names>ZH</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cryo-EM of full-length α-synuclein reveals fibril polymorphs with a common structural kernel</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>3609</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-05971-2</pub-id><pub-id pub-id-type="pmid">30190461</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lövestam</surname><given-names>S</given-names></name><name><surname>Schweighauser</surname><given-names>M</given-names></name><name><surname>Matsubara</surname><given-names>T</given-names></name><name><surname>Murayama</surname><given-names>S</given-names></name><name><surname>Tomita</surname><given-names>T</given-names></name><name><surname>Ando</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Tarutani</surname><given-names>A</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name><name><surname>Scheres</surname><given-names>SHW</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Seeded assembly in vitro does not replicate the structures of α-synuclein filaments from multiple system atrophy</article-title><source>FEBS Open Bio</source><volume>11</volume><fpage>999</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.1002/2211-5463.13110</pub-id><pub-id pub-id-type="pmid">33548114</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>MR</given-names></name><name><surname>Hu</surname><given-names>ZW</given-names></name><name><surname>Zhao</surname><given-names>YF</given-names></name><name><surname>Chen</surname><given-names>YX</given-names></name><name><surname>Li</surname><given-names>YM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Phosphorylation induces distinct alpha-synuclein strain formation</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>37130</elocation-id><pub-id pub-id-type="doi">10.1038/srep37130</pub-id><pub-id pub-id-type="pmid">27853185</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mammana</surname><given-names>A</given-names></name><name><surname>Baiardi</surname><given-names>S</given-names></name><name><surname>Rossi</surname><given-names>M</given-names></name><name><surname>Franceschini</surname><given-names>A</given-names></name><name><surname>Donadio</surname><given-names>V</given-names></name><name><surname>Capellari</surname><given-names>S</given-names></name><name><surname>Caughey</surname><given-names>B</given-names></name><name><surname>Parchi</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Detection of prions in skin punch biopsies of Creutzfeldt-Jakob disease patients</article-title><source>Annals of Clinical and Translational Neurology</source><volume>7</volume><fpage>559</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1002/acn3.51000</pub-id><pub-id pub-id-type="pmid">32141717</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masuda-Suzukake</surname><given-names>M</given-names></name><name><surname>Nonaka</surname><given-names>T</given-names></name><name><surname>Hosokawa</surname><given-names>M</given-names></name><name><surname>Oikawa</surname><given-names>T</given-names></name><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Mann</surname><given-names>DMA</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Prion-like spreading of pathological α-synuclein in brain</article-title><source>Brain</source><volume>136</volume><fpage>1128</fpage><lpage>1138</lpage><pub-id pub-id-type="doi">10.1093/brain/awt037</pub-id><pub-id pub-id-type="pmid">23466394</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKeith</surname><given-names>IG</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Halliday</surname><given-names>G</given-names></name><name><surname>Taylor</surname><given-names>J-P</given-names></name><name><surname>Weintraub</surname><given-names>D</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Galvin</surname><given-names>J</given-names></name><name><surname>Attems</surname><given-names>J</given-names></name><name><surname>Ballard</surname><given-names>CG</given-names></name><name><surname>Bayston</surname><given-names>A</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Blanc</surname><given-names>F</given-names></name><name><surname>Bohnen</surname><given-names>N</given-names></name><name><surname>Bonanni</surname><given-names>L</given-names></name><name><surname>Bras</surname><given-names>J</given-names></name><name><surname>Brundin</surname><given-names>P</given-names></name><name><surname>Burn</surname><given-names>D</given-names></name><name><surname>Chen-Plotkin</surname><given-names>A</given-names></name><name><surname>Duda</surname><given-names>JE</given-names></name><name><surname>El-Agnaf</surname><given-names>O</given-names></name><name><surname>Feldman</surname><given-names>H</given-names></name><name><surname>Ferman</surname><given-names>TJ</given-names></name><name><surname>Ffytche</surname><given-names>D</given-names></name><name><surname>Fujishiro</surname><given-names>H</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Goldman</surname><given-names>JG</given-names></name><name><surname>Gomperts</surname><given-names>SN</given-names></name><name><surname>Graff-Radford</surname><given-names>NR</given-names></name><name><surname>Honig</surname><given-names>LS</given-names></name><name><surname>Iranzo</surname><given-names>A</given-names></name><name><surname>Kantarci</surname><given-names>K</given-names></name><name><surname>Kaufer</surname><given-names>D</given-names></name><name><surname>Kukull</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>VMY</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Lewis</surname><given-names>S</given-names></name><name><surname>Lippa</surname><given-names>C</given-names></name><name><surname>Lunde</surname><given-names>A</given-names></name><name><surname>Masellis</surname><given-names>M</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>McLean</surname><given-names>P</given-names></name><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Moreno</surname><given-names>E</given-names></name><name><surname>Mori</surname><given-names>E</given-names></name><name><surname>Murray</surname><given-names>M</given-names></name><name><surname>O’Brien</surname><given-names>JT</given-names></name><name><surname>Orimo</surname><given-names>S</given-names></name><name><surname>Postuma</surname><given-names>RB</given-names></name><name><surname>Ramaswamy</surname><given-names>S</given-names></name><name><surname>Ross</surname><given-names>OA</given-names></name><name><surname>Salmon</surname><given-names>DP</given-names></name><name><surname>Singleton</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name><name><surname>Tiraboschi</surname><given-names>P</given-names></name><name><surname>Toledo</surname><given-names>JB</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Tsuang</surname><given-names>D</given-names></name><name><surname>Walker</surname><given-names>Z</given-names></name><name><surname>Yamada</surname><given-names>M</given-names></name><name><surname>Kosaka</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium</article-title><source>Neurology</source><volume>89</volume><fpage>88</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000004058</pub-id><pub-id pub-id-type="pmid">28592453</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melki</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>How the shapes of seeds can influence pathology</article-title><source>Neurobiology of Disease</source><volume>109</volume><fpage>201</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2017.03.011</pub-id><pub-id pub-id-type="pmid">28363800</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papp</surname><given-names>MI</given-names></name><name><surname>Kahn</surname><given-names>JE</given-names></name><name><surname>Lantos</surname><given-names>PL</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome)</article-title><source>Journal of the Neurological Sciences</source><volume>94</volume><fpage>79</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/0022-510x(89)90219-0</pub-id><pub-id pub-id-type="pmid">2559165</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peelaerts</surname><given-names>W</given-names></name><name><surname>Bousset</surname><given-names>L</given-names></name><name><surname>Van der Perren</surname><given-names>A</given-names></name><name><surname>Moskalyuk</surname><given-names>A</given-names></name><name><surname>Pulizzi</surname><given-names>R</given-names></name><name><surname>Giugliano</surname><given-names>M</given-names></name><name><surname>Van den Haute</surname><given-names>C</given-names></name><name><surname>Melki</surname><given-names>R</given-names></name><name><surname>Baekelandt</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>α-Synuclein strains cause distinct synucleinopathies after local and systemic administration</article-title><source>Nature</source><volume>522</volume><fpage>340</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1038/nature14547</pub-id><pub-id pub-id-type="pmid">26061766</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Gathagan</surname><given-names>RJ</given-names></name><name><surname>Covell</surname><given-names>DJ</given-names></name><name><surname>Medellin</surname><given-names>C</given-names></name><name><surname>Stieber</surname><given-names>A</given-names></name><name><surname>Robinson</surname><given-names>JL</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Pitkin</surname><given-names>RM</given-names></name><name><surname>Olufemi</surname><given-names>MF</given-names></name><name><surname>Luk</surname><given-names>KC</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>VM-Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies</article-title><source>Nature</source><volume>557</volume><fpage>558</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0104-4</pub-id><pub-id pub-id-type="pmid">29743672</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poggiolini</surname><given-names>I</given-names></name><name><surname>Gupta</surname><given-names>V</given-names></name><name><surname>Lawton</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>El-Turabi</surname><given-names>A</given-names></name><name><surname>Querejeta-Coma</surname><given-names>A</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>Sixel-Döring</surname><given-names>F</given-names></name><name><surname>Foubert-Samier</surname><given-names>A</given-names></name><name><surname>Pavy-Le Traon</surname><given-names>A</given-names></name><name><surname>Plazzi</surname><given-names>G</given-names></name><name><surname>Biscarini</surname><given-names>F</given-names></name><name><surname>Montplaisir</surname><given-names>J</given-names></name><name><surname>Gagnon</surname><given-names>J-F</given-names></name><name><surname>Postuma</surname><given-names>RB</given-names></name><name><surname>Antelmi</surname><given-names>E</given-names></name><name><surname>Meissner</surname><given-names>WG</given-names></name><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Ben-Shlomo</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>MT</given-names></name><name><surname>Parkkinen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies</article-title><source>Brain</source><volume>145</volume><fpage>584</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1093/brain/awab431</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prusiner</surname><given-names>SB</given-names></name><name><surname>Woerman</surname><given-names>AL</given-names></name><name><surname>Mordes</surname><given-names>DA</given-names></name><name><surname>Watts</surname><given-names>JC</given-names></name><name><surname>Rampersaud</surname><given-names>R</given-names></name><name><surname>Berry</surname><given-names>DB</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Oehler</surname><given-names>A</given-names></name><name><surname>Lowe</surname><given-names>JK</given-names></name><name><surname>Kravitz</surname><given-names>SN</given-names></name><name><surname>Geschwind</surname><given-names>DH</given-names></name><name><surname>Glidden</surname><given-names>DV</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><name><surname>Middleton</surname><given-names>LT</given-names></name><name><surname>Gentleman</surname><given-names>SM</given-names></name><name><surname>Grinberg</surname><given-names>LT</given-names></name><name><surname>Giles</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism</article-title><source>PNAS</source><volume>112</volume><fpage>E5308</fpage><lpage>E5317</lpage><pub-id pub-id-type="doi">10.1073/pnas.1514475112</pub-id><pub-id pub-id-type="pmid">26324905</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raymond</surname><given-names>GJ</given-names></name><name><surname>Race</surname><given-names>B</given-names></name><name><surname>Orrú</surname><given-names>CD</given-names></name><name><surname>Raymond</surname><given-names>LD</given-names></name><name><surname>Bongianni</surname><given-names>M</given-names></name><name><surname>Fiorini</surname><given-names>M</given-names></name><name><surname>Groveman</surname><given-names>BR</given-names></name><name><surname>Ferrari</surname><given-names>S</given-names></name><name><surname>Sacchetto</surname><given-names>L</given-names></name><name><surname>Hughson</surname><given-names>AG</given-names></name><name><surname>Monaco</surname><given-names>S</given-names></name><name><surname>Pocchiari</surname><given-names>M</given-names></name><name><surname>Zanusso</surname><given-names>G</given-names></name><name><surname>Caughey</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Transmission of CJD from nasal brushings but not spinal fluid or RT-QuIC product</article-title><source>Annals of Clinical and Translational Neurology</source><volume>7</volume><fpage>932</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1002/acn3.51057</pub-id><pub-id pub-id-type="pmid">32538552</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sano</surname><given-names>K</given-names></name><name><surname>Atarashi</surname><given-names>R</given-names></name><name><surname>Ishibashi</surname><given-names>D</given-names></name><name><surname>Nakagaki</surname><given-names>T</given-names></name><name><surname>Satoh</surname><given-names>K</given-names></name><name><surname>Nishida</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Conformational properties of prion strains can be transmitted to recombinant prion protein fibrils in real-time quaking-induced conversion</article-title><source>Journal of Virology</source><volume>88</volume><fpage>11791</fpage><lpage>11801</lpage><pub-id pub-id-type="doi">10.1128/JVI.00585-14</pub-id><pub-id pub-id-type="pmid">25078700</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sano</surname><given-names>K</given-names></name><name><surname>Atarashi</surname><given-names>R</given-names></name><name><surname>Satoh</surname><given-names>K</given-names></name><name><surname>Ishibashi</surname><given-names>D</given-names></name><name><surname>Nakagaki</surname><given-names>T</given-names></name><name><surname>Iwasaki</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Murayama</surname><given-names>S</given-names></name><name><surname>Mishima</surname><given-names>K</given-names></name><name><surname>Nishida</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Prion-like seeding of misfolded α-synuclein in the brains of dementia with lewy body patients in RT-QUIC</article-title><source>Molecular Neurobiology</source><volume>55</volume><fpage>3916</fpage><lpage>3930</lpage><pub-id pub-id-type="doi">10.1007/s12035-017-0624-1</pub-id><pub-id pub-id-type="pmid">28550528</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schweighauser</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Tarutani</surname><given-names>A</given-names></name><name><surname>Kametani</surname><given-names>F</given-names></name><name><surname>Murzin</surname><given-names>AG</given-names></name><name><surname>Ghetti</surname><given-names>B</given-names></name><name><surname>Matsubara</surname><given-names>T</given-names></name><name><surname>Tomita</surname><given-names>T</given-names></name><name><surname>Ando</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>K</given-names></name><name><surname>Murayama</surname><given-names>S</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Scheres</surname><given-names>SHW</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structures of α-synuclein filaments from multiple system atrophy</article-title><source>Nature</source><volume>585</volume><fpage>464</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2317-6</pub-id><pub-id pub-id-type="pmid">32461689</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahnawaz</surname><given-names>M</given-names></name><name><surname>Tokuda</surname><given-names>T</given-names></name><name><surname>Waragai</surname><given-names>M</given-names></name><name><surname>Mendez</surname><given-names>N</given-names></name><name><surname>Ishii</surname><given-names>R</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Soto</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Development of a biochemical diagnosis of Parkinson disease by detection of α-synuclein misfolded aggregates in cerebrospinal fluid</article-title><source>JAMA Neurology</source><volume>74</volume><fpage>163</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2016.4547</pub-id><pub-id pub-id-type="pmid">27918765</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahnawaz</surname><given-names>M</given-names></name><name><surname>Mukherjee</surname><given-names>A</given-names></name><name><surname>Pritzkow</surname><given-names>S</given-names></name><name><surname>Mendez</surname><given-names>N</given-names></name><name><surname>Rabadia</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Schmeichel</surname><given-names>A</given-names></name><name><surname>Singer</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Tsai</surname><given-names>AL</given-names></name><name><surname>Shirani</surname><given-names>H</given-names></name><name><surname>Nilsson</surname><given-names>KPR</given-names></name><name><surname>Low</surname><given-names>PA</given-names></name><name><surname>Soto</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy</article-title><source>Nature</source><volume>578</volume><fpage>273</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-1984-7</pub-id><pub-id pub-id-type="pmid">32025029</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siderowf</surname><given-names>A</given-names></name><name><surname>Concha-Marambio</surname><given-names>L</given-names></name><name><surname>Lafontant</surname><given-names>DE</given-names></name><name><surname>Farris</surname><given-names>CM</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Urenia</surname><given-names>PA</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Alcalay</surname><given-names>RN</given-names></name><name><surname>Chahine</surname><given-names>LM</given-names></name><name><surname>Foroud</surname><given-names>T</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Kieburtz</surname><given-names>K</given-names></name><name><surname>Merchant</surname><given-names>K</given-names></name><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Poston</surname><given-names>KL</given-names></name><name><surname>Seibyl</surname><given-names>J</given-names></name><name><surname>Simuni</surname><given-names>T</given-names></name><name><surname>Tanner</surname><given-names>CM</given-names></name><name><surname>Weintraub</surname><given-names>D</given-names></name><name><surname>Videnovic</surname><given-names>A</given-names></name><name><surname>Choi</surname><given-names>SH</given-names></name><name><surname>Kurth</surname><given-names>R</given-names></name><name><surname>Caspell-Garcia</surname><given-names>C</given-names></name><name><surname>Coffey</surname><given-names>CS</given-names></name><name><surname>Frasier</surname><given-names>M</given-names></name><name><surname>Oliveira</surname><given-names>LMA</given-names></name><name><surname>Hutten</surname><given-names>SJ</given-names></name><name><surname>Sherer</surname><given-names>T</given-names></name><name><surname>Marek</surname><given-names>K</given-names></name><name><surname>Soto</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Assessment of heterogeneity among participants in the Parkinson’s Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study</article-title><source>The Lancet. Neurology</source><volume>22</volume><fpage>407</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(23)00109-6</pub-id><pub-id pub-id-type="pmid">37059509</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>WW</given-names></name><name><surname>Margolis</surname><given-names>RL</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Troncoso</surname><given-names>JC</given-names></name><name><surname>Lee</surname><given-names>MK</given-names></name><name><surname>Dawson</surname><given-names>VL</given-names></name><name><surname>Dawson</surname><given-names>TM</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><name><surname>Ross</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells</article-title><source>The Journal of Neuroscience</source><volume>25</volume><fpage>5544</fpage><lpage>5552</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0482-05.2005</pub-id><pub-id pub-id-type="pmid">15944382</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spillantini</surname><given-names>MG</given-names></name><name><surname>Schmidt</surname><given-names>ML</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Jakes</surname><given-names>R</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Alpha-synuclein in Lewy bodies</article-title><source>Nature</source><volume>388</volume><fpage>839</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1038/42166</pub-id><pub-id pub-id-type="pmid">9278044</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spillantini</surname><given-names>MG</given-names></name><name><surname>Crowther</surname><given-names>RA</given-names></name><name><surname>Jakes</surname><given-names>R</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies</article-title><source>PNAS</source><volume>95</volume><fpage>6469</fpage><lpage>6473</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.11.6469</pub-id><pub-id pub-id-type="pmid">9600990</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strohäker</surname><given-names>T</given-names></name><name><surname>Jung</surname><given-names>BC</given-names></name><name><surname>Liou</surname><given-names>S-H</given-names></name><name><surname>Fernandez</surname><given-names>CO</given-names></name><name><surname>Riedel</surname><given-names>D</given-names></name><name><surname>Becker</surname><given-names>S</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><name><surname>Bennati</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>WS</given-names></name><name><surname>Lee</surname><given-names>S-J</given-names></name><name><surname>Zweckstetter</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Structural heterogeneity of α-synuclein fibrils amplified from patient brain extracts</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>5535</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-13564-w</pub-id><pub-id pub-id-type="pmid">31797870</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanudjojo</surname><given-names>B</given-names></name><name><surname>Shaikh</surname><given-names>SS</given-names></name><name><surname>Fenyi</surname><given-names>A</given-names></name><name><surname>Bousset</surname><given-names>L</given-names></name><name><surname>Agarwal</surname><given-names>D</given-names></name><name><surname>Marsh</surname><given-names>J</given-names></name><name><surname>Zois</surname><given-names>C</given-names></name><name><surname>Heman-Ackah</surname><given-names>S</given-names></name><name><surname>Fischer</surname><given-names>R</given-names></name><name><surname>Sims</surname><given-names>D</given-names></name><name><surname>Melki</surname><given-names>R</given-names></name><name><surname>Tofaris</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Phenotypic manifestation of α-synuclein strains derived from Parkinson’s disease and multiple system atrophy in human dopaminergic neurons</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>3817</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-23682-z</pub-id><pub-id pub-id-type="pmid">34155194</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uversky</surname><given-names>VN</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Fink</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson’s disease and heavy metal exposure</article-title><source>The Journal of Biological Chemistry</source><volume>276</volume><fpage>44284</fpage><lpage>44296</lpage><pub-id pub-id-type="doi">10.1074/jbc.M105343200</pub-id><pub-id pub-id-type="pmid">11553618</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Perren</surname><given-names>A</given-names></name><name><surname>Gelders</surname><given-names>G</given-names></name><name><surname>Fenyi</surname><given-names>A</given-names></name><name><surname>Bousset</surname><given-names>L</given-names></name><name><surname>Brito</surname><given-names>F</given-names></name><name><surname>Peelaerts</surname><given-names>W</given-names></name><name><surname>Van den Haute</surname><given-names>C</given-names></name><name><surname>Gentleman</surname><given-names>S</given-names></name><name><surname>Melki</surname><given-names>R</given-names></name><name><surname>Baekelandt</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies</article-title><source>Acta Neuropathologica</source><volume>139</volume><fpage>977</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1007/s00401-020-02157-3</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>JC</given-names></name><name><surname>Giles</surname><given-names>K</given-names></name><name><surname>Oehler</surname><given-names>A</given-names></name><name><surname>Middleton</surname><given-names>L</given-names></name><name><surname>Dexter</surname><given-names>DT</given-names></name><name><surname>Gentleman</surname><given-names>SM</given-names></name><name><surname>DeArmond</surname><given-names>SJ</given-names></name><name><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Transmission of multiple system atrophy prions to transgenic mice</article-title><source>PNAS</source><volume>110</volume><fpage>19555</fpage><lpage>19560</lpage><pub-id pub-id-type="doi">10.1073/pnas.1318268110</pub-id><pub-id pub-id-type="pmid">24218576</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woerman</surname><given-names>AL</given-names></name><name><surname>Stöhr</surname><given-names>J</given-names></name><name><surname>Aoyagi</surname><given-names>A</given-names></name><name><surname>Rampersaud</surname><given-names>R</given-names></name><name><surname>Krejciova</surname><given-names>Z</given-names></name><name><surname>Watts</surname><given-names>JC</given-names></name><name><surname>Ohyama</surname><given-names>T</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Widjaja</surname><given-names>K</given-names></name><name><surname>Oehler</surname><given-names>A</given-names></name><name><surname>Sanders</surname><given-names>DW</given-names></name><name><surname>Diamond</surname><given-names>MI</given-names></name><name><surname>Seeley</surname><given-names>WW</given-names></name><name><surname>Middleton</surname><given-names>LT</given-names></name><name><surname>Gentleman</surname><given-names>SM</given-names></name><name><surname>Mordes</surname><given-names>DA</given-names></name><name><surname>Südhof</surname><given-names>TC</given-names></name><name><surname>Giles</surname><given-names>K</given-names></name><name><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Propagation of prions causing synucleinopathies in cultured cells</article-title><source>PNAS</source><volume>112</volume><fpage>E4949</fpage><lpage>E4958</lpage><pub-id pub-id-type="doi">10.1073/pnas.1513426112</pub-id><pub-id pub-id-type="pmid">26286986</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woerman</surname><given-names>AL</given-names></name><name><surname>Kazmi</surname><given-names>SA</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Aoyagi</surname><given-names>A</given-names></name><name><surname>Oehler</surname><given-names>A</given-names></name><name><surname>Widjaja</surname><given-names>K</given-names></name><name><surname>Mordes</surname><given-names>DA</given-names></name><name><surname>Olson</surname><given-names>SH</given-names></name><name><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>Familial Parkinson’s point mutation abolishes multiple system atrophy prion replication</article-title><source>PNAS</source><volume>115</volume><fpage>409</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1073/pnas.1719369115</pub-id><pub-id pub-id-type="pmid">29279394</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woerman</surname><given-names>AL</given-names></name><name><surname>Kazmi</surname><given-names>SA</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Freyman</surname><given-names>Y</given-names></name><name><surname>Oehler</surname><given-names>A</given-names></name><name><surname>Aoyagi</surname><given-names>A</given-names></name><name><surname>Mordes</surname><given-names>DA</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><name><surname>Middleton</surname><given-names>LT</given-names></name><name><surname>Gentleman</surname><given-names>SM</given-names></name><name><surname>Olson</surname><given-names>SH</given-names></name><name><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>MSA prions exhibit remarkable stability and resistance to inactivation</article-title><source>Acta Neuropathologica</source><volume>135</volume><fpage>49</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1007/s00401-017-1762-2</pub-id><pub-id pub-id-type="pmid">28849371</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woerman</surname><given-names>AL</given-names></name><name><surname>Oehler</surname><given-names>A</given-names></name><name><surname>Kazmi</surname><given-names>SA</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><name><surname>Middleton</surname><given-names>LT</given-names></name><name><surname>Gentleman</surname><given-names>SM</given-names></name><name><surname>Mordes</surname><given-names>DA</given-names></name><name><surname>Spina</surname><given-names>S</given-names></name><name><surname>Grinberg</surname><given-names>LT</given-names></name><name><surname>Olson</surname><given-names>SH</given-names></name><name><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Multiple system atrophy prions retain strain specificity after serial propagation in two different Tg(SNCA*A53T) mouse lines</article-title><source>Acta Neuropathologica</source><volume>137</volume><fpage>437</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1007/s00401-019-01959-4</pub-id><pub-id pub-id-type="pmid">30690664</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woerman</surname><given-names>AL</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Kazmi</surname><given-names>SA</given-names></name><name><surname>Oehler</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Mordes</surname><given-names>DA</given-names></name><name><surname>Olson</surname><given-names>SH</given-names></name><name><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Kinetics of α-synuclein prions preceding neuropathological inclusions in multiple system atrophy</article-title><source>PLOS Pathogens</source><volume>16</volume><elocation-id>e1008222</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008222</pub-id><pub-id pub-id-type="pmid">32017806</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamasaki</surname><given-names>TR</given-names></name><name><surname>Holmes</surname><given-names>BB</given-names></name><name><surname>Furman</surname><given-names>JL</given-names></name><name><surname>Dhavale</surname><given-names>DD</given-names></name><name><surname>Su</surname><given-names>BW</given-names></name><name><surname>Song</surname><given-names>ES</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Kotzbauer</surname><given-names>PT</given-names></name><name><surname>Diamond</surname><given-names>MI</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Parkinson’s disease and multiple system atrophy have distinct α-synuclein seed characteristics</article-title><source>The Journal of Biological Chemistry</source><volume>294</volume><fpage>1045</fpage><lpage>1058</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.004471</pub-id><pub-id pub-id-type="pmid">30478174</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Schweighauser</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Kotecha</surname><given-names>A</given-names></name><name><surname>Murzin</surname><given-names>AG</given-names></name><name><surname>Garringer</surname><given-names>HJ</given-names></name><name><surname>Cullinane</surname><given-names>PW</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Foroud</surname><given-names>T</given-names></name><name><surname>Warner</surname><given-names>TT</given-names></name><name><surname>Hasegawa</surname><given-names>K</given-names></name><name><surname>Vidal</surname><given-names>R</given-names></name><name><surname>Murayama</surname><given-names>S</given-names></name><name><surname>Revesz</surname><given-names>T</given-names></name><name><surname>Ghetti</surname><given-names>B</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Lashley</surname><given-names>T</given-names></name><name><surname>Scheres</surname><given-names>SHW</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Structures of α-synuclein filaments from human brains with Lewy pathology</article-title><source>Nature</source><volume>610</volume><fpage>791</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05319-3</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec sec-type="appendix" id="s8"><title>Cases</title><p>The clinical diagnosis of Parkinson’s disease patients was performed using the UK Parkinson’s Disease Brain Bank criteria, followed by a neurologist review (<xref ref-type="bibr" rid="bib14">Daniel and Lees, 1993</xref>). PDD patients were diagnosed using the Movement Disorder Society task force PDD diagnostic criteria (<xref ref-type="bibr" rid="bib15">Dubois et al., 2007</xref>). DLB patients were diagnosed using the DLB consortium diagnostic criteria (<xref ref-type="bibr" rid="bib37">McKeith et al., 2017</xref>). MSA patients were diagnosed based on the MSA consensus statement (<xref ref-type="bibr" rid="bib20">Gilman et al., 1998</xref>). All PD, PDD, and DLB subjects had neuropathologically confirmed Lewy body pathology. Neuropathological diagnosis of MSA subjects was based on degeneration of striatonigral and olivopontocerebellar regions combined with glial cytoplasmic aSyn inclusions (<xref ref-type="bibr" rid="bib39">Papp et al., 1989</xref>). Braak αSyn and tau stages were assessed according to the protocol outlined by BrainNet Europe (<xref ref-type="bibr" rid="bib1">Alafuzoff et al., 2008</xref>; <xref ref-type="bibr" rid="bib2">Alafuzoff et al., 2009</xref>). Specifically, Braak αSyn stages were assigned by examining the distribution of αSyn inclusions in the medulla, pons, midbrain, basal ganglia, hippocampus, cingulate gyrus, temporal, frontal and parietal cortices. Braak tau stages were assigned based on tau immunostains across regions of the visual cortex, the middle temporal gyrus, the anterior hippocampus and the posterior hippocampus.</p></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92775.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mistry</surname><given-names>Pramod K</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Yale University</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group><kwd-group kwd-group-type="evidence-strength"><kwd>Solid</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> work compares the strain properties of a-synuclein fibrils isolated from LBD and MSA patient samples with the resulting amplified fibrils following SAA. Using orthogonal biochemical and structural approaches to strengthen their analyses, the authors provide <bold>solid</bold> evidence that the SAA-amplified fibrils do not recapitulate the disease-relevant strains present in the patient samples. CryoEM would further strengthen this data but it is outside the scope of the work. This work should be considered in the widespread applications of SAA in synucleopathies and its potential limitations.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92775.3.sa1</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Most neurodegenerative diseases are characterized by the self-templated misfolding of a particular protein in a manner that enables progressive spread throughout the central nervous system. In diseases including Parkinson's disease (PD) and multiple system atrophy (MSA), the protein a-synuclein misfolds into unique strains, which use this self-replicating mechanism to encode disease-specific information. Previous research suggests that a major contributor to the lack of successful clinical trials across neurodegenerative diseases is the lack of disease-relevant strains used in preclinical testing. While MSA patient samples are known to replicate efficiently in cell and mouse models of disease, Lewy body disease (LBD) patient samples do not. To overcome this obstacle, the seeding amplification assay (SAA) uses recombinant a-synuclein to amplify the misfolded protein structure present in a human patient sample. The resulting fibrils are then widely used by many laboratories as a model of PD. In this manuscript, Lee et al., set out to compare the strain properties of a-synuclein fibrils isolated from LBD and MSA patient samples with the resulting amplified fibrils following SAA. Using orthogonal biochemical and structural approaches to strengthen their analyses, the authors report that the SAA-amplified fibrils do not recapitulate the disease-relevant strains present in the patient samples. Moreover, their data suggest that regardless of which strain is used to seed the SAA reaction, the same strain is generated. These results clearly demonstrate that the SAA-amplified material is likely not disease-relevant. SAA fibrils are broadly used throughout academic and pharmaceutical laboratories. They are used in ongoing drug discovery efforts and recombinant fibrils broadly inform much of what is known about a-synuclein strain biology in LBD patients. The implications of the reported work are, therefore, expansive. These findings add to the growing ledger of reasons that the use of SAA fibrils in research should be halted until improved methods for amplification with high fidelity are developed.</p></body></sub-article><sub-article article-type="author-comment" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92775.3.sa2</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Selene Seoyun</given-names></name><role specific-use="author">Author</role><aff><institution>University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Civitelli</surname><given-names>Livia</given-names></name><role specific-use="author">Author</role><aff><institution>University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Parkkinen</surname><given-names>Laura</given-names></name><role specific-use="author">Author</role><aff><institution>University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer 1 (Public Review):</bold></p><p>Comment 1. Clinical Data on Patient Brain Samples: The inclusion of specific details such as postmortem intervals and the age at disease onset for patient brain samples would be valuable. These factors could significantly affect the quality of the tissues and their relevance to the study. Moreover, given the large variation in disease duration between PD and PDD, it’s important to consider disease duration as a potential confounding factor, especially when concluding that PDD patients have a more severe form of synucleinopathy compared to PD.</p></disp-quote><p>We thank the reviewer for this valuable comment. We have included the post-mortem interval (PMI) and age of death in Table S1, showing the clinicopathological information. Changes on page 16. As suggested by the reviewer, we included the discussion on the large variation in disease duration between PD and PDD cases. We noted that DLB cases also have shorter disease durations but still demonstrate seeding kinetics similar to PDD. Therefore, we hypothesise that the molecular differences we observed between different diseases were due to the strain properties or higher pathological load (seen in both PDD and DLB) and are unlikely due to the disease duration. Changes on pages 9-11, lines 204-212.</p><disp-quote content-type="editor-comment"><p>Comment 2. Inclusion of Healthy Controls in Multiple Tests: Given the importance of healthy controls in scientific studies, especially those involving human brain samples, the authors could consider using healthy controls in more tests to strengthen the robustness of the findings. Expanding the use of healthy controls in biochemical profiling and phosphorylation profiles would provide a better basis for comparison and clarify the significance of results in a disease context. This will help the authors to elaborate on the interpretation of results, for example, in Figure 3, where the authors claim that PD brains show mostly monomeric _α<italic>Syn forms (line 119 and 120, and also in 222 and 223). Whether it implies the absence of alpha-syn pathology in PD brains? If there are differences from healthy controls? What are these low molecular weight bands (¡15kD) (line 125-126) and whether they are also present in healthy controls? Also, we do not have a perfect pS129-specific (anti-p</italic>α_Syn) antibody. They are known for non-specific labeling. Investigating the phosphorylation levels in healthy controls and comparing them to PD brains, especially considering the predominance of monomeric (healthy _α_Syn?) in PD brains, would help clarify the observed changes.</p></disp-quote><p>We agree with the reviewer’s assessment and consider this an important suggestion. We performed biochemical profiling and immunogold imaging with the three HC cases and presented the results in Figure 4. aSyn in healthy controls was completely digested by PK. The low MW bands were absent in PD and HC, and there was no difference in the PK profiles. However, this may be due to the low pathology load and amount of pathological aSyn in the selected PD brains. Additional comments were added to the results. Changes are on pages 4 (lines 136-137) and page 7 (Figure 4).</p><disp-quote content-type="editor-comment"><p>Comment 3. Age of Healthy Controls: Providing information about the age at death for healthy controls is crucial, as age can impact the accumulation of aSyn. Also include if the brain samples were age-matched, or analyses were age-adjusted.</p></disp-quote><p>We have described the age of each patient, and the analyses were age-adjusted. Changes on page 16 (Table S1).</p><disp-quote content-type="editor-comment"><p>Comment 4. Braak Staging Discrepancy: The study reports the same Braak staging for both PD and PDD, despite the significant difference in disease duration. Maybe other reviewers with clinical experience might have a better take on this. This observation merits discussion in the paper, allowing readers to better understand the implications of this finding.</p></disp-quote><p>ddressed: Our PD and PDD cases are Braak stage 6, indicating that the LB pathology had progressed to the neocortex. It‘s important to note that Braak stage represents only where the LB pathogy has spread and does not indicate anything about the load of LBs. However, our immunohistochemistry results (page 20) show that PDD demonstrates a higher LB load than PD cases in the entorhinal cortex. As the reviewer has suggested, this comment has been amended in the manuscript. Changes on pages 9-11, lines 204-212.</p><disp-quote content-type="editor-comment"><p>Comment 5. Citation of Relevant Studies: The paper should consider citing and discussing a recent celebrated study on PD biomarkers that used thousands of cerebrospinal fluid (CSF) samples from different PD patient cohorts to demonstrate the effectiveness of SAA as a biochemical assay for diagnosing PD and its subtypes.</p></disp-quote><p>As suggested by the reviewer, we included this study in the discussion. Changes on page 12, lines 275-278.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer 3 (Public Review):</bold></p><p>The experiments are missing two important controls. (1) what to fibrils generated by different in vitro fibril preparations made from recombinant synclein protein look like; and (2) the use of CSF from the same patients whose brain tissue was used to assess whether CSF and brain seeds look and behave identically. The latter is perhaps the most important question of all - namely how representative are CSF seeds of what is going on in patients’ brains?</p></disp-quote><p>We thank the reviewers for this valuable comment. Although in vitro preformed fibrils (PFFs) made out of recombinant aSyn are still important sources for cellular and animal studies to generate disease models and investigate mechanisms, many studies have now turned to use human brain amplified fibrils considering them to more closely present the human structure. Therefore, our study was designed to specifically address this hypothesis by comparing e human derived and SAA-amplified fibrils. It would be interesting to compare these structures also to PFFs but this was beyond the scope of our study. Comparing the CSF and brain seed from the same patients would be very interesting indeed but also difficult as this would require biosample collection during life followed by brain donation. The SAA cannot be done from the PM CSF due to contamination with blood. However, we are in a privileged position to examine such a comparison soon with our longitudinal Discovery cohort, where some participants have donated their brains. These future studies will address the critical question of whether the CSF seeds reflect those in the brain.</p><disp-quote content-type="editor-comment"><p>In their discussion the authors do not comment on the obvious differences in the conditions leading to the formation of seeds in the brain and in the artificial conditions of the seeding assay. Why should the two sets of conditions be expected to yield similar morphologies, especially since the extracted fibrils are subjected to harsh conditions for solubilization and re-suspension.</p></disp-quote><p>We agree with the reviewer that the formation of seeds in the brain and the SAA reaction conditions are very different, and one would not expect similar fibrillar morphologies. However, the theory is that pathological seeds are known to amplify through templated seeding, where seeds copy their intrinsic properties to the growing SAA fibrils. Thus, numerous studies use the SAA fibrils as model fibrils to investigate the different aSyn strains. Our study aimed to test whether the SAA fibrils are representative models of the brain fibrils. We included a more explicit comment on this discussion. Changes on page 3, lines 78-83.</p><disp-quote content-type="editor-comment"><p>Finally, the key experiment was not performed - would the resultant seeds from SAA preparations from the different nosological entities produce different pathologies when injected into animal brains? But perhaps this is the subject of a future manuscript.</p></disp-quote><p>We agree this is an essential experiment to build on our conclusion. Animal studies would be imperative to assess whether the SAA fibrils reflect the brain fibrils’ toxicity. However, these were beyond the scope of the present study but are being performed in collaboration with some expert groups.</p><disp-quote content-type="editor-comment"><p>Furthermore, the authors comment on phosphorylation patterns, stating that the resultant seeds are less heavy phosphorylated than the original material. Again, this should not be surprising, since the SAA assay conditions are not known to contain the enzymes necessary to phosphorylate synuclein. The discussion of PTMs is limited to pS-129 phosphorylation. What about other PTMs? How does the pattern of PTMs affect the seeding pattern.</p></disp-quote><p>We agree with the reviewer that other PTMs should be explored, but this was beyond the scope of this study. Here, we could focus on pS129, which has multiple reliable antibodies that also work with immunogold-TEM.</p><disp-quote content-type="editor-comment"><p>Lastly, the manuscript contains no data on how the diagnostic categories were assigned at autopsy. This information should be included in the supplementary material.</p></disp-quote><p>Clinical and neuropathological diagnostic criteria are now included in Table S1. Changes on page 16, lines 448-461.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer 1 (Recommendations for the authors):</bold></p><p>(1) Remove a duplicate sentence in line 94-96.</p></disp-quote><p>Addressed: Thank you for pointing this out. The duplicated sentence has been corrected. Changes are on page 4, lines 105-106.</p><disp-quote content-type="editor-comment"><p>(2) Figure 1 Placement of Healthy Controls: Moving the graph representing healthy controls from the supplementary materials to the main figures could help readers better appreciate the results of diseased states.</p></disp-quote><p>The healthy control SAA curves were moved to the main figure. Changes are on page 5, Figure 2.</p><disp-quote content-type="editor-comment"><p>(3) Commenting on Case 2 Healthy Control: In the discussion section, you may comment on the case of the healthy control that showed amplification towards the end. While definitive conclusions may be challenging, acknowledging the possibility of incidental Lewy bodies or the prodromal phase of the disease would add depth to the analysis? But make sure to include the age information for healthy controls.</p></disp-quote><p>We believe this is an important point to discuss in the manuscript. We have referenced other studies with similar observations and stated that it is currently unknown what this phenomenon reflects (page 11, lines 221-226). The age information of the healthy control subjects was added to Table S1.</p><disp-quote content-type="editor-comment"><p>(4) Figure S3 Clarity: To enhance the clarity of Figure S3, consider adding a reference marker or arrow in the low-magnification image that points to the region being magnified in the insets. This visual cue will make it easier for readers to connect the detailed insets with the corresponding area in the broader image.</p></disp-quote><p>In Figure S3, we included a reference arrow in the low-magnification images to clarify where the higher-magnification images are taken. Changes are on page 19, Figure S3.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer 2 (Recommendations for the authors):</bold></p><p>(1) A major issue confronting the field is the conflation of the PMCA and RT-QuIC assays (the latter of which was used here). The decision to rename and combine the two under the umbrella of SAAs does a major disservice to the field for many reasons. Recognizing that the push for this did not come from the authors, clarifying the differences in their Introduction would be very useful. I suggest this, in large part, because in the prion field, PMCA is known to amplify prion strains with high fidelity whereas the product from RT-QuIC does not. In fact, the RT-QuIC product for PrP is not even infectious, while the synuclein field uses it as a means to generate material for subsequent studies. Highlighting these differences would certainly strengthen the arguments the authors are making about the inadequacy of the synuclein RT-QuIC approach in research.</p></disp-quote><p>We thank the reviewers for these very valuable comments. We have included a further introduction on PMCA and RT-QuIC, explaining the differences and clearly stating our selection of the RT-QuIC method in this paper (page 3, lines 55-68). In addition, we have highlighted that, unlike PMCA, the RT-QuIC end-products are non-infectious and biologically dissimilar to the seed protein. Combined with our results, the findings demonstrate the methodological limitation of RT-QuIC in reproducing the seed fibrils and replicating their intrinsic biophysical information.</p><disp-quote content-type="editor-comment"><p>(2) On page 4, sentences starting on lines 94 and 95 are a duplication.</p></disp-quote><p>The duplicated sentence has been corrected. Changes are on page 4, lines 105-106.</p><disp-quote content-type="editor-comment"><p>(3) In the Results, noting that the pSyn staining on the RT-QuIC fibrils is coming from the human patient sample used to seed the reaction would be useful. This is mentioned in the Discussion, but the lack of mention in the Results made me pause reading to double check the methods. I think this could also be addressed a bit more clearly in the Abstract.</p></disp-quote><p>We have clarified this in the Results and Abstract. Changes on page 1 (lines 21-22) and page 9 (lines 192-194)</p><disp-quote content-type="editor-comment"><p>(4) On page 8 line 188, change was to were in the sentence, ”First, faster seeding kinetics was...”</p></disp-quote><p>This grammar error has been corrected. Changes are on page 9, line 200.</p><disp-quote content-type="editor-comment"><p>(5) The authors may want to comment on the unexpected finding that despite the RT-QuIC fibrils having a difference in twisted vs straight filaments, all 4 seeded reactions gave identical results in the conformational stability assay.</p></disp-quote><p>Addressed: We want to thank the reviewer for this comment and have highlighted the unexpected finding with a comment on what could be causing the identical results in the conformational stability assay. Changes are on page 12, lines 297-303.</p></body></sub-article></article>